Cell Competition in heart development and homeostasis.

Doctoral thesis

Cristina Villa del Campo

Diciembre 2014

Director: Miguel Torres Sánchez
Tutor: Pablo Gómez del Arco
This work was performed in Miguel Torres’ laboratory in the Cardiovascular Developmental Biology and Repair Department at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) in Madrid

This study was funded by grants RD06/0010/0008 (TerCel RETICS), RD12/0019/0005 (TerCel RETICS), BFU2009-08331 (MICINN), S2010/BMD-2315 (Comunidad de Madrid) and BFU2012-31086 (MINECO).

Cristina Villa del Campo has a FPI fellowship from the MINECO (BFU2009-08331)
The only way to make sense out of change is to move with it and join the dance
(Alan Watts)
**Ex vivo** assays. Explants ______________________________________ 51
- Epicardium __________________________________________________ 51
  - Proepicardium ____________________________________________ 51
  - Embryonic myocardium ____________________________________ 52
- RNA isolation from adult hearts _________________________________ 52
- RNASeq. Data analysis ________________________________________ 52
  - RNASeq library production ________________________________ 52
  - RNASeq data analysis ___________________________________ 53
- Image acquisition ____________________________________________ 53
- Image analysis ______________________________________________ 53
  - Myc levels _______________________________________________ 53
  - EYFP/ECFP proportion ____________________________________ 53
  - EYFP levels ______________________________________________ 53
  - Cell area ________________________________________________ 53
  - 3D reconstructions _______________________________________ 53
- Statistical analysis ___________________________________________ 54

**RESULTS** ____________________________________________________ 55
- Cell competition in the developing heart ________________________ 57
  - Myc family expression in the developing heart ________________ 57
- Generation of random genetic mosaics in the developing heart through the *iMOS* system ________________________________ 58
- Mosaic Myc overexpression induces cardiomyocyte population expansion in the developing heart ______________________________________ 59
- Mosaic Myc overexpression in the embryonic heart provokes no pathological hyperplasia _________________________________ 60
- Islet1 progenitors are highly sensitive to Myc induced competition ______ 62
- Cell proliferation does not account for the expansion of the Myc-overexpressing cardiomyocyte population ______________________ 64
- Myc-overexpressing cardiomyocyte population expands by apoptosis-driven cell competition______________________________ 66
- Flower is not involved in Myc induced cell competition in the heart__ 68
- Endogenous cell competition does not play a role in the heart _____ 68
- Mycn and Myc levels interplay in cell competition in the heart______ 70
- Myc induced competition during adult heart homeostasis ____________ 72
  - Myc overexpression induces cardiomyocyte population expansion in the adult heart _________________________________ 75
  - Analysis of the pathways involved in adult cardiomyocyte competition 76
- Cell competition in the developing epicardium _____________________ 81

**DISCUSSION** __________________________________________________ 91

**CONCLUSIONS** _________________________________________________ 99

**BIBLIOGRAPHY** _______________________________________________ 105
INDEX of FIGURES

Figures

Figure 1. Cell competition and supercompetition in *Drosophila*’s wing disc __________ 27
Figure 2. Cell competition and cell selection are multistep processes ___________ 28
Figure 3. Model depicting how endogenous cell competition was defined ________ 29
Figure 4. Overview of early heart development __________________________________ 35
Figure 5. Epicardium and its contribution to the developing heart ________________ 36
Figure 6. Schematic representation of the iMOS system construction _______________ 45
Figure 7. Exercise protocol ______________________________________________________ 51
Figure 8. Myc is dispensable for heart development _____________________________ 57
Figure 9. Mosaic Myc overexpression driven by *Nkx2.5-Cre* in the developing heart 58
Figure 10. Myc-overexpressing population shows an expansion at P0 ____________ 60
Figure 11. Myc-overexpressing cardiomyocyte population expands in thedeveloping heart ___________________________________________________________ 61
Figure 12. Morphometric analysis in newborn mice of cardiomyocytes exposed to Myc overexpression during gestation ________________________________________ 62
Figure 13. Myc-overexpressing cardiomyocytes upon mosaic induction in Islet1+progenitors show an enhanced expansion at P0 _____________________________ 63
Figure 14. Myc-overexpressing cardiomyocytes upon induction in Islet1 progenitors show an early expansion ____________________________________________ 64
Figure 15. Analysis of cell proliferation upon Myc mosaic overexpression in the developing heart _________________________________________________________________________________________________ 65
Figure 16. Myc overexpressing cardiomyocytes expand by inducing apoptosis ofneighbouring WT cardiomyocytes ____________________________________________ 66
Figure 17. *Flower* is dispensable for induced cell competition in the developing heart _________________________________________________________________ 69
Figure 18. p35 rescued cells do not show a decrease in their Myc levels _________ 70
Figure 19. *Mycn* KO shows enhanced Myc induced cell competition in the developing heart _____________________________________________________________ 71
Figure 20. Mosaic Myc overexpression in adult cardiomyocytes is phenotypicallysilent ________________________________________________________________ 73
Figure 21. Myc overexpression induces replacement of adult cardiomyocytes ____ 74
Figure 22. Transcriptomic analysis of the changes induced by Myc mosaic overexpression in the adult heart. Ingenuity pathway analysis __________________________ 76
Figure 23. Transcriptomic analysis of the changes induced by Myc mosaic overexpression in the adult heart. Top networks differentially expressed

Figure 24. Nppa is upregulated in iMOS^{Tt-Myc} mosaic

Figure 25. Analysis of BrDU incorporation in postnatal hearts

Figure 26. Analysis of autophagy in postnatal hearts

Figure 27. Myc overexpression enhances Wt1 lineage contribution to the developing heart contribution to the developing heart

Figure 28. Increased contribution of EYFP-Myc cells from Wt1 lineage at E14.5

Figure 29. Myc-induced Cell Competition takes place in epicardium and epicardium derived cells. Myc overexpression promotes contribution of Wt1 lineage to the developing myocardium

Figure 30. Contribution of EYFP-Myc cells to Smooth muscle lineage is enhanced

Figure 31. Coculture assays show enhanced invasiveness in iMOS^{Tt-Myc}; Wt1-Cre epicardium

Figure 32. Myc expression does not induce differentiation to cardiomyocytes from IVS region or endocardial/endothelial lineage

Figure 33. Proepicardium explants give rise to cardiomyocytes spontaneously as opposed to epicardial explants regardless of Myc expression

Figure 34. Cardiomyocyte contribution of Wt1 lineage appears previous to epicardial colonization

Figure 35. Schematic model on the results obtained in this thesis in cell competition in the developing and adult heart

Tables

Table 1. Tables that summarize the reagents and solutions used in the adult cardiomyocyte isolation protocol

Table 2. Table that summarizes the swimming protocol followed for the physiological hypertrophy protocol created through exercise
Abbreviations

AHF: Anterior heart field
ANP: Atrial Natriuretic peptide (also Nppa)
AVC: Atrioventricular canal
Bcl2: B cell leukemia/lymphoma 2
Bmp: Bone morphogenetic protein
Bst: Belly spot and tail
Cdk4: Cyclin-dependent kinase 4
Cnc: Cardiac neural crest
Dpp: Decapentaplegic
ECFP: Enhanced cyan fluorescent protein
ECM: Extracellular matrix
EGF: Epidermal growth factor
EMT: epithelial to mesenchymal transition
EPDCs: Epicardial derived cells
EYFP: Enhanced Bellow fluorescent protein
FHF: First heart field
Fwe: Flower
iMOS: Inducible mosaics
ISH: In situ hybridization
IVS: Interventricular septum
LV: Left Ventricle
MEF2C: Myocyte enhancer factor 2C
mESC: Mouse embryonic stem cell
MI: Myocardial infarction
Myc: Myelocytomatosis oncogene
Mycn: v-myc myelocytomatosis viral related oncogene, neuroblastoma derived
Myh6: myosin, heavy polypeptide 6, cardiac muscle, alpha
Nppa: See ANP
OFT: Outflow tract
PE: Proepicardium
PHH3: Phoshoistone 3
PI3K: Phosphatidylinositol 3-kinase
Tbx18: T-box18
TGFβ: Transforming Growth Factor beta
VFW: Ventricular free wall
WT: Wild-type
Wt1: Wilms tumor 1 homolog
SUMMARY

It is my ambition to say in ten sentences what others say in a whole book
(Friedrich Nietzsche)
Heterogeneous anabolic capacity in cell populations can trigger a phenomenon known as cell competition, through which less active cells are eliminated. Cell competition has been induced experimentally in stem/precursor cell populations in insects and mammals and takes place endogenously in early mouse embryonic cells. Here we show that cell competition can be efficiently induced in mouse cardiomyocytes by mosaic overexpression of Myc both during gestation and adult life. The expansion of the Myc-overexpressing cardiomyocyte population is driven by the elimination of wild type cardiomyocytes, which happens through apoptosis in the embryonic heart and autophagic cell death in the adult cardiomyocytes. Importantly, this cardiomyocyte replacement is phenotypically silent and does not affect heart anatomy or function. Myc overexpression in the adult heart induces a cardioprotective response through the reactivation of fetal programs.

Moreover, cell competition induction in the epicardium during development shows an increased contribution of this lineage to cardiac myocytes. These results show that capacity for cell competition in mammals is not restricted to stem cell populations and suggest that stimulated cell competition has potential as a cardiomyocyte replacement strategy.
La heterogeneidad en la eficiencia anabólica de una población celular desencadena un fenómeno que se conoce como Competición Celular, mediante el cual las células metabólicamente menos activas son eliminadas. La competición celular se ha inducido experimentalmente en poblaciones de células madre/progenitoras en insectos y mamíferos y se ha demostrado que ocurre de forma endógena en células madre embrionarias de ratón. En esta tesis demostramos que la competición celular puede inducirse en cardiomiocitos de ratón mediante sobreexpresión en mosaico de Myc, tanto en desarrollo como en el corazón adulto. La expansión de los cardiomiocitos que sobreexpresan Myc tiene lugar debido a la eliminación de los cardiomiocitos salvajes. Cabe resaltar que este reemplazo de cardiomiocitos ocurre de manera fenotípicamente silenciosa y no afecta a la anatomía o función cardiacas. Aún más, la inducción de competición celular en el epicardio (que ha demostrado ser una población celular con características de células progenitoras) durante el desarrollo da lugar a un aumento en la contribución de dicho linaje a cardiomiocitos. Estos resultados demuestran que la capacidad de competir en células de mamífero no se restringen a poblaciones de células madre y se propone que el estímulo de esta capacidad celular podría tener potencial en estrategias de reemplazo de cardiomiocitos.
INTRODUCTION

The journey of a thousand miles begins with one step (Lao Tzu)
Cell competition has only recently been described to be a mechanism that ensures cell fitness during mammalian development (Claveria et al., 2013).

However, whether it is a universal feature to all cells and tissues in the embryo or restricted to pluripotent cells in the epiblast, remains to be determined. In this thesis we address how cell competition can be induced in the developing heart as well as in adult cardiomyocytes in homeostatic conditions.

Moreover, we explore the possibility of inducing cell competition among heart lineages with regenerative potential; thus addressing the putative use of cell competition in heart regeneration approaches.

Cell competition

During evolution, multicellular organisms have evolved different ways to ensure the proper development of their organs and tissues. Such mechanisms rely on complex interactions between cells and depend on the integration of different signals that will lead to cell survival or cell death. If cells fail to receive appropriate signals from their neighbours they undergo programmed cell death (Raff 1992).

Such dependence on specific survival signals provides a way to eliminate misplaced cells, to regulate cell numbers and, perhaps, to select for the fittest cells; ensuring the maintenance of the homeostasis of the whole organism.

One such mechanism that has been proposed to ensure homeostasis is cell competition, a mechanism by which fitter cells in a given context colonize the tissue at the expense of viable but less fit cells, which are eliminated by induction of apoptosis. Therefore, cell competition is acting as a quality control system to eliminate suboptimal cells.

Cell competition has been defined under various contexts and comprises different types of competitive interactions; but a main feature that underlies cell competition is the elimination of cells that are viable on their own but actively eliminated when confronted with more competitive cells.

Broadly, cell competition can be classified in three types regarding the characteristics of the cells that are in competition (figures 1 y 3).

- Canonical cell competition (Morata and Ripoll, 1975): In this type of cell competition wild-type (WT) cells outcompete neighbouring cells that are somehow defective in their competitive ability; but that are viable when growing

![Cell competition](image)

**Figure 1. Cell competition and supercompetition in Drosophila's wing disc**

Schematic representation of cell competition as was first described in Drosophila's experiments. In cell competition model, Minute/+ cells were confronted with WT fitter cells and undergo apoptotic elimination. Wild-type cells overproliferated at the expense of Minute/+ loser cells colonizing the final wing.

In supercompetition induced by Myc, (Moreno and Basler 2004) dMyc clones are generated in a wild-type background; and these dMyc cells overproliferate at the expense of WT loser cells that are eliminated by apoptosis. Arrows represent an unknown signal that drives apoptosis-driven cell competition after fitness comparison.
in an homotypic enviroment.

- Supercompetition: (Moreno and Basler 2004) Supercompetitor cells have been genetically modified; and this modification confers them a competitive advantage over wild-type cells; which are outcompeted when growing in a mosaic fashion.

- Endogenous cell competition: (Claveria, et al. 2013)

Endogenous cell competition has only very recently been described, in contrast with the previously mentioned types. It has been proposed to select for fitter cells in an homeostatic context; without being experimentally-induced.

The studies leading to the description of these three types of cell competition as well as factors implicated in one or more competitive interactions is described further down; but all three types share the non-cell-autonomous elimination of “loser cells”, that are only defined by the tissue context.

A little bit of history: lessons from the fly

First observation of the phenomenon now termed cell competition was reported almost 40 years ago by Ginés Morata and Pedro Ripoll (Morata and Ripoll, 1975)(reviewed in Diaz and Moreno, 2005) using Drosophila’s wing disc, where two different cell populations that differed in metabolic rates were confronted; and it was shown that cells that would have otherwise been viable were eliminated when growing in the presence of cells that were metabolically more active. This experiment was performed using Minute flies, which carry a mutation in ribosomal proteins, lacking full ribosome machinery. Homozygous Minute flies are lethal, but when the mutation is carried in heterozigosity, they are viable and develop forming normal flies of the right size, albeit at a slower rate.

However, when Minute/+ (M+) cells were

---

**Figure 2. Cell competition and cell selection are multistep processes.**

Schematic of the regulation of loser cell elimination, that includes all described pathways involved in cell competition. Coloured rectangles show different layers of regulation. Cell selection is initiated by mutations or pathways that lead to a gain or a loss of fitness (light blue). This modulation of fitness leads to the deficit or gain of some limiting factors for which cells are competing (grey). This then activates cell fitness markers (Flower, Sparc; green). Eventually, loser cell death is induced by different cell autonomous signal (JNK, Hid; Dark brown: LOSER FATE), and by non-cell autonomous signals emitted by winner cells (light brown). Hypothetical relationships are marked by dashed lines that are highlighted in purple.

(Modified from (Levayer and Moreno 2013).)
growing in a mosaic wing in direct confrontation with wild type cells, they were completely eliminated (Morata and Ripoll 1975). The conclusion from this was that Minute cells, although viable on their own, were eliminated when they had to grow among wild-type cells, metabolically more active.

This model was supported by several studies that followed. Simpson (Simpson, 1979) used a starvation model, that allowed to reduce growth rates in the wing disc. It was described that, in starvation conditions, M/+ cell elimination happened at a slower rate, and their final proportion in the disc was higher. This way it was demonstrated that differences in growth rates driven by metabolic activity (abolished upon starvation) underlaid Minute/+ cell competition (Simpson, 1979; reviewed in de Beco et al., 2012).

It wasn’t until many years later that some light was shed on the phenomenon of cell competition. In 2002 a study was published reporting that cells in the imaginal disc could be competing for survival or growth factor signals and that differences in ligand capture mediated the elimination of M/+ cells.

In the model proposed, cells compete for a secreted protein involved in cell survival, Decapentaplegic (Dpp; member of the TGFβ family) (Moreno et al., 2002; reviewed in Gallant, 2005, Milan, 2002). They reproduced classic experiments using Minute mutants and defined that M/+ cells were eliminated by apoptosis when confronted with a WT population. This was confirmed by showing how blocking apoptosis using the baculoviral inhibitor p35 reduced cell competition. It was described that in Minute cells, uptake of Dpp signal is defective, leading to apoptotic cell death. In this model, suboptimal cells would have a reduced Dpp uptake, which would lead to their elimination.

Despite the relevance of this study and the description of the ligand capture model, many mechanistic questions remained unanswered. The relevance of the ligand-capture model and other trophic theories for cell competition is still disputed; since, besides the condition of a limiting amount of survival factor; a system that enables the comparison of cell fitness is needed. (Adachi-Yamada and O’Connor, 2002, Gibson and

**Heterogeneous Myc levels**  **Cell competition**  **Refined Myc levels**

**E6.5**  **E9.5**

Figure 3. Model depicting how endogenous cell competition was defined

In the Mouse epiblast during normal development, Myc levels are intrinsically heterogeneous and endogenous cell competition refines the epiblast cell population through the elimination of cells with low relative Myc levels. Thus, cell competition naturally contributes to the selection of the epiblast cell pool. (Modified from (Claveria et al., 2013)
**Supercompetition**

In 2004 two papers linking cell competition to the proto-oncogen \(d\text{Myc}\) generated a new wave of interest in this process. \(d\text{Myc}\) is a fly homolog of the mammalian family of Myc transcription factors (which includes Myc, Mycn and \(L\text{-Myc}\)), and it is able to regulate the expression of many genes involved in cell proliferation, growth, and the cell’s anabolic machinery, including ribosome biogenesis (reviewed in de la Cova and Johnston, 2006; Bellosta and Gallant, 2010).

These two papers studied the role of \(d\text{Myc}\) in cell competition and its implications by inducing clonal \(d\text{Myc}\) overexpression in the wing disc (de la Cova et al., 2004, Moreno and Basler, 2004). Clones expressing high levels of \(d\text{Myc}\) were able to expand at the expense of wild type cells until they filled the compartment. This expansion required the elimination of wild-type cells by apoptosis. In this context wild-type cells behaved as “losers” and thus \(d\text{Myc}\) overexpressing cells were termed “supercompetitors”.

It was also shown that these supercompetitor cells (expressing two additional copies of \(d\text{Myc}\)) behaved as “winners” when confronted with wild type cells but were “losers” if confronted with cells expressing four extra \(d\text{Myc}\) copies (Moreno and Basler, 2004).

This supported the idea that it’s not absolute \(d\text{Myc}\) levels that drive cell competition but rather the relative \(d\text{Myc}\) in a given cell population.

Moreover, cell competition was not a simple outcome of cell overproliferation, since overexpression of different known factors inducing cell growth (\(\text{PI3K}, \text{Dp110}\)) or cell cycle regulators (\(\text{CyclinD and Cdk4}\)) was unable to eliminate wild-type cells however much the clone expanded (Moreno and Basler, 2004; de la Cova et al., 2004).

In this context, \(d\text{Myc}\) deficient cells can be comparable to \textit{Minute/+} cells, suggesting that the force driving cell competition is \(d\text{Myc}\) control over the cell’s anabolic machinery. As in \textit{Minute} classic experiments, \(d\text{Myc}\)-overexpressing clones only expanded within their compartment until final growth was reached.

There are, however, some differences between classic cell competition and supercompetition, since it has been described that \textit{Minute}-driven cell competition required cell-cell contact (Martin et al., 2009) and \(d\text{Myc}\)-driven cell competition could be triggered about 10 cell diameters away (de la Cova et al., 2004).

This is consistent with an \textit{in vitro} study performed using \textit{Drosophila}’s cells in which conditioned media from cell competition could induce a competitive response (Senoo-Matsuda and Johnston, 2007).

All of these data further support the idea that it is the relative anabolic activity (fitness) between neighbouring cells what drives cell competition and that some sensing mechanism has to allow cells to communicate their fitness status to its neighbours.

**Other players involved in cell competition in \textit{Drosophila}**

Recently other pathways have been linked to cell competition, either more players in the already described cell competition or novel pathways that affect cell competition in different ways (shown in full detail in figure 2), adding more factors that trigger cell competition, more mediators or cell-cell signals implicated.

We will only mention some of them since in-depth analysis of these pathways falls out of the scope of this thesis.

Regarding which factors are able to induce cell competition; they can roughly be characterized in two groups:

1.- Those that involve differences in ana-
bolic ability, resulting in different growth ra- 

tes; which were the first shown triggers of ce- 
llicompetition (Morata and Ripoll, 1975, More- 

2.- Those in which epithelial integrity is al- 
ted. Cells lacking basolateral proteins such as Scribble, undergo apoptosis in the presen- 

cence of wild-type cells. (Norman et al., 2012).

Even if we will not describe this in detail, 

These isoforms were also expressed in lo- 
ser cells in Minute induced cell competition 
(Rhiner et al., 2010).

These isoforms: fwe

2. INTRODUCTION

Engulfment as a requirement for cell 
competition?

Studies of cell competition performed using 
Minute mutants showed that competitive cell 
death of M/+ cells by WT clones that expan- 
ded at their expense, usually happened where- 
both cell populations were adjacent.

This suggested the existence of winner/lo- 
ser contact-dependent induction of cell dea- 
th, and hinted for a requirement of loser cell 
engulfment by winner cells for cell competi- 
tion to occur (Li and Baker, 2007; reviewed in Li and Baker, 2007). It also addressed the question of the fate of the outcompeted bo- 
dies and how they are eliminated from the 
tissue, since initial observations claimed that 
apoptotic cells were extruded from the tissue 
and accumulated basally (Moreno and Bas- 
lar, 2004).

It was described that M/+ cells adjacent 
to WT population were 5-10x more likely to 
undergo apoptosis than cells that weren’t in contact. Moreover, corpses of M/+ cells 
were typically found within the cytoplasm of 
WT cells. This led to the thought that engulf- 
ment played a major role in loser cell corpse 
clearance. To test this, genes involved in en- 
gulfment were mutated, which resulted in an 
abrogation of cell competition (Li and Baker, 

2007).

However, these results have not been re- 
produced (Lolo et al., 2012; reviewed in Lolo 
et al., 2013), and it has also been proposed 
that engulfment was only required for the 
elimination of already delaminated cells and 
mostly performed by haemocytes since win- 
ner cells didn’t need to express engulfment 
genes for cell competition to occur.

This reopened the question of the mecha- 
nism responsible for the elimination of loser 
cell corpses and also of the meaning of loser 
cell increased apoptosis at clonal bounda- 
ries.

The Flower code

A possible mechanism that could explain 
apoptosis of loser cells in clonal boundaries 
would be a cell-cell communication of the 
cell’s fitness status that would lead to the eli- 
mination of the less fit cell. Such mechanism 
would require the presence of a fitness mar- 
ker that would allow cells to compare each 
other’s anabolic status.

Using gene expression arrays, several ge- 
nes that were expressed during cell competi- 
tion were identified. One of those genes was 
a membrane calcium channel involved in 
endocytosis and exocytosis. Further assays 
lead to propose it as a mechanism that would 
allow neighbouring cells to report their fit- 
ness: Flower (fwe) (Rhiner et al., 2010). Fwe 
protein contains 3 to 4 transmembrane do- 
mains and it is found in three isoforms, which 
express different C-terminal regions exposed 
to the extracellular space. One of Flower’s 
isoforms is predominant and it is expressed in WT cells: fwe\textsuperscript{Llose}. By induction of supercom- 
petition driven by dMyc overexpression, WT 
loser clones were found to express two other 
isoforms: fwe\textsuperscript{Llose-A} and fwe\textsuperscript{Llose-B}.

These isoforms were also expressed in lo- 
er cells in Minute induced cell competition 
(Rhiner et al., 2010).
If Fwe\textsuperscript{Lose} isoforms were forcibly expressed in wild-type cells homogenously, no effect was observed. However, when they were expressed in clones, they strongly induced apoptosis.

Moreover, upon reduction of the Fwe\textsuperscript{Lbs} levels in clones, this effect was also observed, suggesting that the ability of Fwe to induce cell death is strongly context dependent, relying on the cell-cell differences in Fwe isoform expression.

Loss of Fwe expression doesn’t affect non-competitive growth of the tissue; therefore Fwe is proposed to be a downstream effector of cell competition, labelling loser cells and leading to their elimination.

The regulation mechanism by which \textit{fwe} mRNA is alternatively spliced into \textit{Ubi}or \textit{Lose} forms is still to be determined, as well as how this extracellular code is interpreted in order to lead to cell death or cell survival.

**Cell competition relevance for cancer**

All of these studies leave an open question on whether cell competition is a universal feature in metazoans, since it could have potential implications in homeostasis, cancer and regeneration. Several studies have linked cell competition to genes implicated in cancer, such as \textit{Myc} but also the tumor suppressor pathway Hippo (Tyler et al., 2007; Chen et al., 2012), Jak/Stat signalling pathway (Rodrigues et al., 2012) and tumor suppressor p53 (de la Cova et al., 2014).

It is thought that cell competition could be implicated in the growth of tumour cells, linking supercompetition with the precancerous fields model, in which these lesions could colonize the tissue by eliminating surrounding cells (Rhiner and Moreno, 2009, de Beco et al., 2012; reviewed in Baker and Li, 2008).

However, the role of cell competition in cancer is still unclear, since it has also been proposed to be a mechanism involved in tumour suppression, by driving the elimination of faulty cells; and, when disrupted, promoting the accumulation of cells carrying mutations (Martins et al., 2014; Ballesteros-Arias et al.)

It was then necessary to elucidate the role of cell competition in mammalian models to further understand its possible implications and relevance for cancer.

**Cell competition in mammals**

A couple of early studies had suggested that cell competition could be an extended mechanism among metazoans:

The ‘Belly spot and tail’ (\textit{Bst}) mutation is a mouse equivalent of the fly \textit{Minute} mutants, since these mice are defective in the ribosomal protein L24. As in \textit{Drosophila Minutes}, homozygous \textit{Bst} mice are not viable, whereas heterozygous show decreased pigmentation and a kinked tail, along with some other deficiencies (Oliver et al., 2004). By generating chimaeras it was shown that \textit{Bst/+} cells had a significant growth and survival disadvantage in the presence of wild-type cells (Oliver et al., 2004), however this study did not address whether the observed differences resulted from cell-autonomous features or from cell competition.

A further study was published, suggesting a role for cell competition in liver regeneration (Oertel et al., 2006). Upon partial resection of adult rat liver, fetal liver was transplanted; and it was shown that fetal hepatocytes grafted and proliferated in the host for long periods being able to replace up to 23% of the liver mass. Moreover it was also shown that this repopulation was associated with increased apoptosis of host hepatocytes immediately adjacent to the transplanted fetal ones (Oertel et al., 2006).

Two studies published later assessed the role of the tumour suppressor gene \textit{p53}. A form of cell competition based on stress and mediated by \textit{p53} was described, being re-
tricted to the hematopoietic compartment. In this case, cell competition induced a senescence-like phenotype in outcompeted cells rather than their apoptotic elimination (Bondar and Medzhitov, 2010, Marusyk et al., 2010). When mixed with irradiated wild-type cells, cells with mutant p53 have an advantage and become winners, repopulating hosts more efficiently. In this context, cell competition selects for less damaged cells by comparing p53 levels (Bondar and Medzhitov, 2010).

Loss of epithelial polarity has also been related with cell competition in vitro in several studies (Tamori et al., 2010) which describe for the first time epithelial-integrity related cell competition in mammals. More recently, it has been reported in a mammalian model in vitro how loss of Scribble in clones induced them to be eliminated (Norman et al., 2012).

All of the mentioned assays performed in mammalian systems suggested that cell competition could be a universal characteristic of metazoans.

The reports of cell competition commented, however, involved the experimental introduction of stress or mutations and did not address the potential roles of natural cell competition in normal developmental or tissue homeostasis processes. Clavería and colleagues approached the study of cell competition in mammals by developing a system of inducible mosaics based on Cre recombination (Clavería et al., 2013). Recombination generates two different labelled cell populations; one of which overexpresses Myc under the control of the Rosa26 promoter. Using this system, it was demonstrated that supercompetition could be induced in the mouse epiblast and that it provoked the phenotypically silent replacement of wild type cells.

This replacement relied on apoptosis of WT loser cells that was shown to be contact dependent, as WT cells in direct contact with Myc overexpressing ones showed higher apoptotic rates. Moreover, it was demonstrated that cell competition occurred endogenously in the epiblast. Epiblast pluripotent cells were shown to have high number of naturally occurring apoptotic events and express Myc in an heterogeneous fashion, which was not observed with other pluripotency markers.

It was shown that those epiblast cells undergoing apoptosis were the ones that expressed lower relative Myc levels, and thus, elimination of these cells refined Myc levels of the developing embryo. Rescuing cells by p35 expression showed that their Myc levels were relatively lower than those of the rest of the population (they were “loser” cells), indicating that cells that were eliminated in normal conditions were those which expressed less Myc.

This study also explored cell competition in vitro in mouse embryonic stem cells (mESC).

It was reported for the first time not only that cell competition could be induced in mESC cultures but also that these cultures were also subject to endogenous cell competition, dependent on their differences in endogenous Myc levels. The mechanism for the elimination of loser cells both in the epiblast and in mESC cultures was also explored, and it was shown that those cells with relative lower Myc levels were engulfed by their winner neighbours, shedding some light on the mechanism by which loser cell corpses are eliminated and why cell contact could be a key mechanism in this elimination.

This study was the first to report anabolic endogenous cell competition happening naturally in the developing embryo and proposed a model in which epiblast cells compare their anabolic ability and eliminate those with relative lower fitness, thus refining the overall fitness of the cells that will generate the em-
bryo. Parallel studies have also identified Flower-mediated endogenous cell competition in *Drosophila* for the elimination of supernumerary neurons (Merino et al., 2013).

A second study in mESCs demonstrated cell competition dependent of BMP receptor and Myc levels (Sancho et al., 2013). It is not clear, however, that the phenomena reported are equivalent, since in the Claveria study, Myc-induced cell competition took place in undifferentiated mESCs and required close contact; while in the Sancho et al. study, induced differentiation was required for competition and cell competition could be induced by transferring the supernatant of the cultures.

A more recent example of endogenous cell competition has been reported for T-cell progenitors in the thymus (Martins et al., 2014). It was shown that resident progenitor cells were outcompeted by bone-marrow-derived colonizing cells upon competition for the survival factor Interleukin7 (IL7) and that cell competition is required to replace thymus-resident progenitors with fresh cells from the bone marrow; since abolishment of cell competition in this context led to a cancerous transformation of thymic cells; again suggesting cell competition could play a role in eliminating faulty cells and thus preventing oncogenic responses.

These studies open the door to understanding the role of cell competition in normal organism development and physiology.

Despite the universality of cell competition mechanism (shown to be conserved across metazoans) the studies performed in insects and specially those in mammals seem to link cell competition to cellular stemness or progenitor states, but this hypothesis remains to be tested experimentally.

In this thesis we explore this issue by asking whether cell competition could be induced in one of the first lineages to differentiate in the mammalian embryo, the cardiac lineage.

### Heart development

The heart is the first organ to form in the embryo; and its development is a complex process that involves the integration of many different cell populations that must be incorporated into an already functional organ.

Heart progenitor cells arise from the splanchnic mesoderm that migrate anteriorly during gastrulation to give rise to two regions or fields of cardiac progenitor cells, located at both sides of the midline (reviewed in Rana et al., 2013; Vincent and Buckingham, 2010).

Around day E7.5, these two bilateral regions then fuse at the midline to give rise to what is commonly termed ‘the cardiac crescent’ (figure 4). These cardiac crescent cells migrate to fuse into a heart tube that detaches from the splanchnic mesoderm, and remains only connected to the dorsal pericardial walls by its ends, the arterial and the venous poles.

This primary heart tube mostly contains left ventricle (LV) and atrial precursors, and is referred to as first heart field (FHF), composed by a myocardial layer lined by an internal endocardial layer. However, the majority of the precursors that will form the heart remain in an undifferentiated state medially and posteriorly to the primary cardiac tube.

This second source of cardiac progenitors is commonly termed second heart field (SHF) due to its later contribution to the developing heart, although the nature of the dynamics and molecular mechanisms underlying the restrictions between these two fields of progenitors is still debated.

The first heart field cells upon differentiation lower their proliferation rate and growth of the heart tube at this stage relies mostly on incorporation of SHF progenitors at both poles of the tube (de Boer et al., 2012). These progenitors remain highly proliferative and undifferentiated, and are progressively added
to the heart tube allowing its expansion. At the arterial pole, SHF cells give rise to the RXWÁRZ WUDFW 2)7 WKH ULJKW YHQWULFOH DQG the ventricular septum (Zaffran et al., 2004), whereas at the venous pole, SHF progenitors contribute to atria (although the majority of cells in the atria come form FHF) and atrial septum (Snarr et al., 2008).

While this addition is taking place, the heart undergoes a rightward looping that positions the forming chambers WKDW DUH EHLQJ VSHFLÀHG WKH DWULD EHFR-me displaced cranial to the ventricles. At this point, chamber regions (L V, RV, atria) DUH VSHFLÀHG DQG XQGHUJR D EDORRQLQJ SUR FHVV LQFUHDVLQJ WKHLU SUROLIHUDWLRQ UDWH ORFDOO\ as opposed to valve forming regions, namely atrio-ventricular canal (AVC) which will give ULVH WR PLWUDO DQG WULFXVSLG YDOYHV DQG RXWÁRZ tract (OFT), where pulmonary and aortic valves are formed.

During this phase, the chambers reach their final organization and the myocardial layer thickens forming a layer of projections that invade the heart lumen (the trabecules), which allow the myocardium to meet the cardiac pumping needs and still allow for proper nutrition and gas exchange before the formation of the coronary vessels.

This trabecules emerge at around day E9.5 and last until approximately day E14.5, when the myocardium undergoes compaction, the trabeculae stop growing and thicken, merging with the compact layer of the myocardium.

As these process takes place, the space between trabeculae forms capillaries (reviewed in Samsa et al., 2013).

Afterwards, septation of both atria and ventricles occurs. Cells from neural crest (cardiac neural crest or CNC) also become added to the developing heart and give rise to the separation of the OFT into aorta and pulmonary vein (Kirby and Hutson, 2010).

**Epicardium and its contribution to the developing heart**

The epicardium is the outermost layer of the heart. It derives from an extracardiac structure, the proepicardium (PE), a mass of cells from the coelomic epithelium that forms at the posterior dorsal pericardial wall, near the venous pole of the heart, protruding to
the pericardial cavity, at around E9.5 (reviewed in Perez-Pomares and de la Pompa, 2011).

The proepicardial cells then migrate onto the looping heart and attach to the myocardial surface, where they flatten and adopt their characteristic “cobble-stone” morphology. The epicardium then undergoes a process of EMT (epithelial to mesenchymal transition) and gives rise to EPDCs (epicardial derived cells) that invade the myocardial layer and differentiate into several cell types within the developing heart. EPDCs contribute mostly to form the coronary vessels and interstitial heart fibroblasts (figure 5).

EPDCs have been reported to give rise to endothelial cells (Perez-Pomares et al., 2002) and vascular smooth muscle cells (Mikawa and Gourdie, 1996) in the coronary vessels and to cardiac fibroblasts (Gittenberger-de Groot et al., 1998). Contribution of the epicardium to the cardiomyocyte population has also been reported (Zhou et al., 2008, Cai et al., 2008); but this is still a controversial issue (Christoffels et al., 2009) and remains to be elucidated.

Despite the controversy, EPDCs have been shown to be a multipotent progenitor within the heart (Wessels and Perez-Pomares, 2004).

Moreover, studies in adult mice in a myocardial infarction context upon priming have shown that epicardial cells are able to recapitulate an embryonic program and give rise to new vasculature (Smart et al., 2007) and cardiomyocytes (Smart et al., 2011), which supports the notion that EPDCs in the adult heart can be a source of progenitor cells (Chong et al., 2011) with multiple potentials, and evidences the need for further studies regarding epicardium both in embryonic and in adult context.

**Maintaining the numbers: cell proliferation/renewal in the developing and adult heart**

As mentioned previously, during development, the linear heart tube is a slow proliferating structure and during this phase the heart grows by addition of cells from the SHF; whose high proliferation rates lower upon differentiation (Kelly et al., 2001).
An increase in cell proliferation takes place in the chamber forming regions during the ballooning phase (de Boer et al., 2012).

After that, the fetal heart grows through continuous proliferation. In postnatal stages, proliferation declines and cardiomyocytes undergo binucleation. Thus, there are two distinct cycling phases: the fetal one, resulting in cell division and the postnatal one, which takes place after birth and results in cardiomyocytes entering a quiescent state and undergoing binucleation through lack of cytokinesis. (Soonpaa et al., 1996; Li et al., 1996).

This switch from hyperplastic to hypertrophic growth is tightly linked to binucleation and “terminal differentiation” of cardiomyocytes. Caryokinesis without cytokinesis is therefore associated with the loss of the proliferative capacity.

Moreover, lower vertebrate species in which cardiomyocytes do not undergo binucleation, have been long shown to be able to regenerate part of the heart. In amphibians and fish the ventricle is undivided, and the animal can survive removal of the apex.

It was shown in 1974 that newt heart could undergo a resection of its ventricle and grow it back; while DNA synthesis was detected close to the wound (Oberpriller and Oberpriller, 1974). More recently, the zebrafish has been stablished as a cardiac regeneration model (Poss et al., 2002, Raya et al., 2003).

The fact that mammalian heart underwent a phase of hypertrophic growth and binucleation associated with the loss of proliferative capacity, led to the long-standing belief that the heart was a fully “post-mitotic organ” and unable to regenerate. While this view holds true for the most part of the postnatal life, it has been shown that postnatal heart retains regenerative ability until P7 (postnatal day 7) (Porrello, Mahmoud et al. 2011), coinciding with the cessation of developmental proliferation of cardiomyocytes (Soonpaa et al., 1996).

The question on adult cardiomyocyte turnover rate remains controversial, although it is widely accepted now that some degree of cardiomyocyte renewal takes place in the mammalian adult heart.

Several studies report a low rate of cardiomyocyte renewal in homeostatic conditions both in humans (Bergmann et al., 2009, Kajstura et al., 2010) and rodents (Soonpaa and Field, 1997, Senyo et al., 2013, Ali et al., 2014); and after heart injury, proliferation of cardiomyocytes and cardiomyocyte renewal is increased near the border of the infacted zone (Senyo et al., 2013).

Despite intensive research regarding this topic, the results are intensely debated and proliferation rates of existing cardiomyocytes in the adult heart differ, ranging from 1% (Soonpaa and Field, 1994, Bergmann et al., 2009) to 40% per year (Kajstura et al., 2010).

Interestingly, it has also been shown that inducing cardiomyocyte-restricted Cyclin D2 expression resulted in regenerative growth in injured hearts (Pasumarthi et al., 2005). The proliferative activation of cardiomyocytes led to a clear reduction in scarring and an increased number of cardiomyocytes, concomitant with improved heart function and anatomy following myocardial infarction (MI).

Therefore, new insight on the heart capacity to replenish cardiomyocytes in homeostatic conditions is an interesting lead; and the implications of further studies addressing this issue would be very relevant for the future of cardiovascular medicine.

**Dealing with stress: how the heart responds to physiological and pathological challenges**

In the adult heart, growth of the organ usually corresponds to its functional load. In
responses to changes in demand, the heart triggers a hypertrophic response to counterbalance the increase in wall stress (reviewed in (McMullen and Jennings, 2007).

Hypertrophic responses in the adult heart are broadly classified in physiological and pathological, and although they both share common features they are caused by different stimuli and associated with different molecular and cellular responses (Iemitsu et al., 2001).

Pathological cardiac hypertrophy is associated with hypertension, valve disease, myocardial infarction and genetic causes; whereas physiological hypertrophy occurs during development or early postnatal stages and in response to exercise (Fagard, 1997).

Both of them concur with an increase in myocyte volume and the pathological response involves also a depressed cardiac function. Pathological hypertrophy is usually accompanied by fibrosis and extracellular matrix (ECM) accumulation (Brower et al., 2006), although both types involve remodelling of the ECM.

In pathological hypertrophy there is usually a reactivation of fetal genes, which show an increased expression, such as atrial natriuretic peptide (ANP) (Saito et al., 1987).

The fetal gene program also triggers significant changes in metabolic programs. Myocardial energy metabolism during cardiac hypertrophy presents a shift in fuel consumption similar to that seen in fetal heart tissue: the heart muscle decreases fatty-acid oxidation and increases glucose utilization.

This metabolic change appears to be advantageous by delaying the transition to heart failure (Lopaschuk et al., 2010).

The understanding of the molecular pathways activated under pathological stress conditions will help developing new cardio-protective therapies; and along with further insight in cardiomyocyte turnover promotion,
OBJECTIVES

Only the most naïve of questions are truly serious
(Milan Kundera)
At the light of recent studies pointing to a role of cell competition in refining fitness in pluripotent epiblast cells and the potential relevance of cell competition to cancer, we decided to explore the role of cell competition in differentiated cells, the cardiomyocytes; both during embryonic development and in adult homeostatic conditions. Moreover we addressed the potential role of cell competition in a pool of cardiac cells with potential regenerative ability, the epicardium.

In this study we have induced cell competition in embryonic cardiomyocytes by generating heterogeneity in Myc levels.

Specific aims:

Determine whether induced heterogeneous Myc levels induce cell competition in developing cardiomyocytes and study the mechanisms involved.

Determine whether induced heterogeneous Myc levels induce cell competition during cardiac tissue homeostasis in adult cardiomyocytes and study of the implications for cardiac function.

Determine how cell cardiomyocyte competition affects cardiac adaptation to physiological stress.

Determine the changes in the expression profile upon Myc mosaic expression in cardiomyocytes.

Determine how the epicardium and epicardial-derived lineages respond to Myc-induced cell competition.
MATERIALS AND METHODS

Men have become the tools of their tools
(H.D. Thoreau)
MATERIALS AND METHODS

Animal models

*iMOS* lines. The mosaic lines used in this thesis have been previously described: (Claveria et al., 2013) and are shown in figure 6. *iMOS*<sup>wt</sup> in which both labelled cell populations are WT.

*iMOS<sup>T1-Myc</sup>* in which EYFP population overexpresses Myc and ECFP population is WT.

*iMOS<sup>T1-Myc/T2-p35</sup>* in which EYFP population overexpresses Myc and ECFP population expresses apoptosis inhibitor p35.

*iMOS<sup>T2-p35</sup>* in which EYFP population is WT and ECFP population expresses the apoptosis inhibitor p35.

**Embryo harvest**

Mice embryos were extracted at different developmental stages. Females from different genotypes (usually *iMOS* positive females) were mated with males (usually carrying the Cre recombinase).

To estimate the developmental stage, vaginal plugs were checked every morning. Midday of the day when the vaginal plug was detected was considered gestational day 0.5 (E0.5). Females were sacrificed by CO<sub>2</sub> inhalation and abdominal cavity was opened to expose the

---

**Figure 6. A. Schematic representation of the *iMOS* system construction.**

In this system two pairs of modified lox sites are used, so that upon recombination either of the two possible recombinations will take place at random. Upon Cre expression, either T0 cassette is excised, leading to the expression of T1 (EYFP). Because of the presence of the triple polyadenylation sequence, expression doesn’t progress to T2. If T2 recombination takes place both T0 and T1 are excised leading to the expression of T2 (ECFP). Recombination of this system gives rise to a mosaic, generating at random two labeled cell populations. Expression is under the control of Rosa26 promoter and will give rise to a policistronic mRNA expressing a buffer sequence or a protein of interest and a fluorescent reporter protein, either the yellow fluorescent protein (EYFP) or the cyan fluorescent protein (ECFP).

---

**B Schematic representation of the different *iMOS* Mouse lines used in this thesis.**

In *iMOS*<sup>wt</sup>, both labeled cell populations are random, *iMOS*<sup>T1-c-Myc</sup> generates a EYFP Myc overexpressing population and ECFP WT population. In *iMOS*<sup>T1-c-Myc/T2-p35</sup>, EYFP population overexpresses Myc and ECFP population expresses p35. In *iMOS*<sup>T2-p35</sup>, EYFP population is WT whereas ECFP population expresses p35.
uterus, which was removed by dissection. In cold PBS under the scope in a Petri dish, muscular uterine wall and decidual layer were carefully ripped to expose the embryo, covered which the yolk sac. Yolk sac and Reichter membrane were teared apart and the embryos harvested.

Yolk sac was recovered to use for genotyping purposes in small embryos (in bigger ones, pieces of the embryo such as limbs or tails were preferentially used). This procedure was only done when fluorescent analysis couldn’t be performed or wasn’t sufficient to know the embryo’s genotype.

Embryos were fixed in PFA (Merck) 2% in PBS overnight at 4°C.

**Adult heart dissection**

After sacrificing the mouse by CO2 inhalation, thoracic cavity was opened and ribs cut apart to expose the heart. Heart was dissected and collected in a Petri Dish on cold PBS.

After dissection, cannulation through the aorta was performed and new cold PBS was infused through coronary vessels to remove the blood. If hearts were collected for cryosectioning they were infused through the cannula afterwards with PFA 2%, cut in half and fixed overnight at 4°C.

If fresh confocal imaging was performed, hearts were cut into slices using a blade and imaged directly in PBS on a MatTek Glass Bottom Microwell Dish.

**BrDU and tamoxifen administration**

BrDU (5mg/ml) was administered to pregnant females by intraperitoneal injection 2 hours prior to embryo collection. When using and inducible Cre, recombination was induced by tamoxifen administration by oral gavage (from 2 to 6 mg/female).

BrDU 0.5 mg/ml was administered to adult mice through the drinking water for one month to induce recombination in *My6-merCremer*.

**Whole mount embryo staining**

**Whole mount embryo staining: TUNEL**

When E8.5, E9.5 and 10.5 embryos were harvested, most often staining was performed on the whole embryo to further analyse performing confocal sections. In some cases, heart was dissected previous to the staining; and in other, whole embryos were stained. Following overnight fixation embryos were washed in PBS several times and permeabilized using 0.5% Triton X-100 (Calbiochem) for 30 minutes.

TUNEL staining was performed by pretreating embryos after permeabilization in TUNEL solution (PBS, TdT buffer and CoCl2–TdT kit from Roche) for one hour and then terminal transferase and Biotin-16-dUTPs were added (according to manufacturers’ directions) and incubated for 1h at 37°C. Afterwards, reaction was stopped in Citrate buffer 10mM pH6 for 20 minutes at room temperature. After PBS washes, blocking step in 10% goat serum (Gibco-BRL Life-Technologies) for one hour and then incubation at 4°C with fluorofore coupled with streptavidins (1:500) and DAPI (1:200). On the following day, after several washes embryos were stored in Vectashield solution at 4°C until visualization took place.

Cy-3 and Cy-5 conjugated streptavidins (Jackson ImmunoResearch) were used.

**Whole mount embryo staining: Immunofluorescence**

For immunofluorescence stainings, same procedure was followed as mentioned in the previous paragraph but after permeabilization (performed in 0.25% to 0.5% depending on the antibody), blocking was performed in 10% goat serum for one hour and then incubation
with the primary antibody was performed overnight at 4°C. Following day and after several washes, embryos were incubated with a secondary antibody coupled with a fluorescent protein overnight at 4°C. On the third day, after several washes embryos were ready to be imaged and store, which was performed in Vectashield mounting medium (Vector Laboratories, USA).

Specifically, for BrDU staining, a treatment with DNase I 1:20 (Roche) for 1h at 37°C was performed after permeabilization.

Primary antibodies used were:
- Rabbit anti-phosphohistone 3 polyclonal (Millipore) 1:300
- Rabbit anti-GFP polyclonal (Living Colors) 1:150
- Rabbit anti-LC3 polyclonal (Abgent) 1:100
- Rabbit anti-Beclin polyclonal (Cell signalling) 1:50
- Mouse anti-Troponin T monoclonal (Thermo Scientific) 1:300
- Mouse anti-BrDU monoclonal (Invitrogen) 1:50
- Rabbit anti-Myc polyclonal (Millipore) 1:300
- Rabbit anti-Wt1 polyclonal (SantaCruz) 1:100
- Chick anti-GFP polyclonal (Abcam) 1:200
- Rabbit anti Beclin-1 polyclonal (cell signalling) 1:100
- Rabbit anti Nppa polyclonal (Millipore) 1:200
- Mouse anti Mycn monoclonal (Abcam)

Secondary antibodies used were:
- Cy3-goat anti rabbit 1:500 (Jackson)
- Cy5-goat anti rabbit 1:500 (Jackson)
- Cy3-goat anti mouse 1:500 (Jackson)
- 594-goat anti mouse 1:500 (Invitrogen)
- 488-goat anti chicken 1:500 (Invitrogen)

Whole mount staining: In situ hybridization

Whole mount in situ hybridization was performed on E9.5 embryos to detect *Myc* mRNA (probe used in Claveria et al., 2013). Embryos fixed overnight in PFA 4% at 4°C were bleached with H₂O₂ and then treated with protei-nase K at 20μg/ml for 8 minutes. After that, they were refixed in 0.25% glutaraldehyde in 4% PFA. After incubation in prehybridization solution (50% formamide, 4xSSC pH4.5, 50μg/ml heparine, 20μg/ml tRNA, 7% blocking reagent solution, 1% SDS), probe hybridization was done in that solution overnight at 65°C.

After hybridization, several washes were performed in posthybridization solution I (50% formamide, 5x SSC, 1% SDS) and posthybridization solution II (50% formamide, 2xCCS, 0.1%SDS). Afterwards, embryos were washed in TBST (50mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM KCl, 0.1% Tween20). Next step was blocking in goat serum and incubating in anti Digoxigenin antibody overnight at 4°C. After that, the embryos were washed in NTMT solution (NaCl 100mM, Tris HCl 0.1M, 50mM MgCl2, 0.1% Tween20) and developing of the signal was performed adding BM Purple substrate.

**Tissue processing for cryosectioning**

After overnight fixation, tissue (embryos or adult hearts) was wash in PBS several times and then left in 15% sucrose in PBS overnight at 4°C. Following that, samples were included in a sucrose 15% and gelatin 7.5% (Sigma Aldrich) at 37°C. After that, gelatin blocks are made and cooled at 4°C. Gelatin blocks are frozen at -70°C in isopentane for 1 minute and stored at -80°C.

Cryosections (8 or 10um) were made using a Leica CM1950 Automated Cryostat.

**Immunostaining on gelatin sections**

Gelatin must be removed from the sections by incubating them at 37°C in PBS for 15 minutes. After that, sections were washed and
permeabilized using 0.2% Triton X-100 in PBS for 10 minutes. Blocking was performed in PBS with 10% goat serum for one hour.

Primary antibody was incubated overnight at 4°C. On the following day, sections were washed and DAPI and secondary antibody incubation was done for 45 minutes to 1 hour at room temperature. Afterwards, sections were washed again and mounted in Vectashield to preserve fluorescence.

All antibodies used have been mentioned previously. Other stainings performed were membrane staining through incubation with wheat germ agglutinin (WGA) coupled with Cy3 or 633 (Invitrogen) to analyze cell diameter.

Embryonic heart digestion: plating and citometry

After embryos were harvested, embryonic hearts from stages E11.5 and E14.5 were dissected carefully, removing lungs and vessels in cold PBS under the scope. Hearts were disaggregated in small pieces using microscissors. Small pieces were incubated in 5-10ml of a digestion buffer containing Colagenase II (Worthington) at 4mg/ml and 2.5% trypsin in PBS. Incubation was performed at 37ºC from 15 to 45 minutes depending on size of the heart. When the pieces appeared digested by visual inspection, solution was pipetted carefully to terminally disaggregate the pieces without inducing bubble formation. Solution was then transferred to a 50ml falcon tube through a 40um cell strainer (BD Biosciences). Then, 10ml of Complete DMEM (DMEM (cc) + FBS 10% + Penicillium/Streptoptomycin 1% (Cambrex Bioscience) was added to stop enzymatic reaction.

Afterwards, digestion mix was centrifuged for 5 minutes at 1200 rpm to pellet the cells. Supernatant was removed by aspiration and cells resuspended in a volume of complete DMEM medium depending on the purpose of the isolation.

If cells were going to be analyzed by flow cytometer, samples were resuspended in 500ul-1ml of complete DMEM. Cells were also plated in MatTek glassbottom dishes or in glass coverslips (either way coated with 0.1% gelatin in PBS). In this case, cells were resuspended in 1-2 ml of DMEM complete medium.

Flow cytometer

Isolated cardiac cells from embryonic hearts were analyzed by flow cytometry to quantify EYFP population since ECFP wasn’t detected by flow cytometry. Propidium Iodide was added to the cells to assess viability (1:5000). An LSR Fortessa 4L Flow Cytometer was used for the analysis (Laser wavelengths 488, 640, 405, 561). For the analysis, FACSDiva and FlowJo softwares were used.

Adult cardiomyocyte isolation

Mice were injected with 200ul heparine 30 minutes - 1h before being sacrificed to ensure no clots were formed in the coronary vessels during the procedure.

After sacrificing the mouse by CO₂ inhalation, thoracic cavity was opened and ribs cut apart to expose the heart. Hearts were dissected and collected in a Petri Dish on cold Perfusion Buffer. (For buffers used in this protocol refer to Table1A.) After dissection, hearts were cannulated through the aorta and cannula secured with surgical thread.

To digest the matrix and isolate de cardiomyocytes different buffers were subject to Langendorff perfusion through the aorta (Obame 2008, Sambrano 2002, Zhou 2000). A system that enabled the buffer to enter the heart through the aorta achieved a constant flux by gravity and maintained a constant temperature of 37°C throughout the whole digestion procedure.

After 15 minutes of introducing Perfusion Buffer through the aorta, the solution was chan-
ged to Digestion Buffer (See table 1A) and this solution perfuses the heart for about 10-15 minutes.

After being perfused with digestion Buffer the heart matrix was digested and cardiomyocytes could be collected in a Petri Dish carefully, finishing disaggregation with a Pasteur pipette.

From this point onwards, steps were carried out at room temperature. These isolated cardiomyocytes were transferred to a 50ml Falcon Tube through a 100um strain net, to remove all the remaining matrix.

After that, Stopping Buffer I was added to the cells and incubated for 15-20 minutes (or until all the cardiomyocytes reached the bottom). Supernatant was discarded and cells newly resuspended in Stopping Buffer II in a 15ml Falcon tube. Cells were incubated in Stopping Buffer II about 15-20 minutes or until cardiomyocytes reached the bottom. Supernatant was discarded and then several steps of calcium reintroduction were performed (T1-T5) at 15°C. Cardiomyocytes were then ready to be plated. This was done on laminin-coated MatTek glass bottom dishes or in laminin (BD Biosciences) coated glass round

<table>
<thead>
<tr>
<th>REAGENT</th>
<th>Company</th>
<th>Final concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>Sigma - Aldrich</td>
<td>113mM</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>Sigma - Aldrich</td>
<td>4,7mM</td>
</tr>
<tr>
<td>Potassium phosphate monobasic</td>
<td>Sigma - Aldrich</td>
<td>0,6mM</td>
</tr>
<tr>
<td>Sodium phosphate dibasic</td>
<td>Sigma - Aldrich</td>
<td>0,6mM</td>
</tr>
<tr>
<td>Magnesium sulphate heptahydrate</td>
<td>Sigma - Aldrich</td>
<td>1,2mM</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>Sigma - Aldrich</td>
<td>12mM</td>
</tr>
<tr>
<td>Potassium bicarbonate</td>
<td>Sigma - Aldrich</td>
<td>10mM</td>
</tr>
<tr>
<td>Phenol Red</td>
<td>Sigma - Aldrich</td>
<td>0,032mM</td>
</tr>
<tr>
<td>HEPES salt</td>
<td>Sigma - Aldrich</td>
<td>10mM</td>
</tr>
<tr>
<td>Taurine</td>
<td>Sigma - Aldrich</td>
<td>30mM</td>
</tr>
<tr>
<td>Butanodione monoxide (BDM)</td>
<td>Sigma - Aldrich</td>
<td>10mM</td>
</tr>
<tr>
<td>Glucose</td>
<td>Sigma - Aldrich</td>
<td>5,5mM</td>
</tr>
<tr>
<td>H2O</td>
<td>-</td>
<td>1X</td>
</tr>
<tr>
<td>Liberase TM 100mg</td>
<td>Roche Appl. Biosc</td>
<td>0,2mg/ml</td>
</tr>
<tr>
<td>Trypsin 2,5%</td>
<td>Gibco</td>
<td>0,14mg/ml</td>
</tr>
<tr>
<td>Calcium Chloride 100mM</td>
<td>Sigma - Aldrich</td>
<td>12,5μM</td>
</tr>
<tr>
<td>H2O</td>
<td>-</td>
<td>1X</td>
</tr>
<tr>
<td>Fetal Bovine Serum</td>
<td>Gibco</td>
<td>5%</td>
</tr>
<tr>
<td>Calcium Chloride 10mM</td>
<td>Sigma - Aldrich</td>
<td>12,5μM</td>
</tr>
<tr>
<td>H2O</td>
<td>-</td>
<td>1X</td>
</tr>
<tr>
<td>Fetal Bovine Serum</td>
<td>Gibco</td>
<td>10%</td>
</tr>
<tr>
<td>Calcium Chloride 10mM</td>
<td>Sigma - Aldrich</td>
<td>12,5μM</td>
</tr>
</tbody>
</table>

Table 1. Tables that summarize the reagents and Solutions used in the adult cardiomyocyte isolation protocol.

A Solutions prepared during the isolation procedure
coverslips. Firstly, cardiomyocytes were plated using plating medium and then, after one hour that medium was removed and culture medium was added (again, refer to the table for full composition of buffers and culture mediums). These cardiomyocytes were usually imaged straight after plating but also were fixed overnight at 4°C in 2% PFA to perform immunostaining.

**Adult physiological cardiac stress induced by exercise**

To induce physiological stress in adult mouse hearts, we submitted mice to exercise through swimming for increasing lengths of time everyday in a thermostatized water tank, kept at 37°C. Table 2 summarizes the swimming times that were followed throughout the experiment and figure 7 illustrates the protocol.

**Echocardiography**

Mice were anesthetized by isoflurane inhalation (1.25%) and examined with a 30-MHz transthoracic echocardiography probe. Images were obtained with Vevo 770 (VisualSonics, Toronto, Canada). Short-axis, long-axis, B-mode and two-dimensional M-mode views were obtained as previously described (Cruz-
Adalia et al., 2010). Left ventricle function was estimated from the ejection fraction, obtained from M-mode echocardiographic images by a blinded echocardiography expert. For these measurements, a long- or short-axis view of the heart was selected to obtain an M-mode registration in a line perpendicular to the left ventricular septum and posterior wall at the level of the mitral chordae tendinea.

**Ex vivo assays. Explants**

**Epicardium**

Following method described in (Chen et al., 2002).

To derive primary epicardial cells, embryos from different developmental stages were harvested.

To isolate epicardial cells from E10.5 and E11.5 embryos, hearts were dissected, both atria and the outflow tract region were removed and the ventricles were each cut into two pieces.

Each piece was placed with the epicardial outermost part facing down onto a gelatin covered MatTek Glass bottom Dish (0.1%Gelatin in PBS). These myocardial pieces were cultured in DMEM containing 10% FBS and 1% Penicillium Streptomycin. After 24 to 48 hours, epicardial cells had migrated from the explant and form a monolayer.

At this point, the myocardial explant was removed using forceps and epicardial cells were left to grow for 3-5 days, at which point they were visualized by confocal microscopy and/or fixed for immunostaining in 2%PFA overnight at 4°C.

In order to derive epicardial cells from embryonic hearts from E15.5 to P0, a different technique was used, involving the manual peeling of the outermost epicardial layer from the heart surface and posterior placing of these cells on a gelatin coated MatTek glass bottom dish. Isolated epicardial layers were cultured for 5-7 days in DMEM+FBS 10% + Pen Strept 1%.

Migrating epicardial cells were either analyzed directly in the confocal or fixed in 2%PFA overnight at 4°C for immunostaining.

<table>
<thead>
<tr>
<th>WEEK</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wednesday</th>
<th>Thursday</th>
<th>Friday</th>
<th>S</th>
<th>S</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20</td>
<td>25</td>
<td>Rest</td>
<td>Rest</td>
</tr>
<tr>
<td>2</td>
<td>25</td>
<td>30</td>
<td>35</td>
<td>40</td>
<td>45</td>
<td>Rest</td>
<td>Rest</td>
</tr>
<tr>
<td>3</td>
<td>45</td>
<td>45</td>
<td>45</td>
<td>45</td>
<td>45</td>
<td>Rest</td>
<td>Rest</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>60</td>
<td>Rest</td>
<td>Rest</td>
</tr>
<tr>
<td>5</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>75</td>
<td>Rest</td>
<td>Rest</td>
</tr>
<tr>
<td>6</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>Rest</td>
<td>Rest</td>
</tr>
<tr>
<td>7</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>Rest</td>
<td>Rest</td>
</tr>
<tr>
<td>8</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>Rest</td>
<td>Rest</td>
</tr>
</tbody>
</table>

Table 2. Table that summarizes the swimming protocol followed for the physiological hypertrophy protocol created through exercise.

Animals were subjected to exercise during 8 weeks at increasing times, ranking from 5 to 90 minutes.

**Figure 7. Excercise protocol**

Photograph showing how the exercise protocol was performed.
Proepicardium

This method is extensively described in (Garriock et al., 2014).

Embryos for proepicardium explants were harvested at E9.0, since after E9.5 much of the proepicardium had already transferred onto the heart.

After the embryos were removed from decidua layer and yolk sac, the pericardium was removed using forceps. The proepicardium was identified just under the heart as a “grape-like” clustering of cells. Heart tube was removed and discarded to have better access and proepicardial cells were removed using forceps.

Proepicardial explants were cultured in DMEM 10% FBS 1% Pens-Strept for 48h on gelatin coated MatTek Glass bottom dishes.

Embryonic myocardium

In some cases, coexplant assays were performed by culturing epicardium (E10.5) with myocardium (E9.0-9.5). Epicardial explant was performed as described previously but in this case, close to the myocardium from the E10.5 heart, the whole heart from a E9.0 embryo was placed, trying to orient the atrioventricular canal region facing the E10.5 explant. After 2-5days these coexplants were fixed in 2% PFA overnight at 4°C for immunostaining.

RNA isolation from adult hearts

In order to perform RNA differential expression analysis, RNA from whole hearts was isolated. Hearts were dissected and washed thoroughly to eliminate blood residue; PBS was run through the aorta by cannulation to ensure coronary vessels were also free as possible from blood residue.

Hearts were then cut into pieces and homogenized in cold trizol reagent (Life Technologies) using the Tissue Lyser. Settings for the tissue lyser were 500 oscillations/second in 1minute cycles. About 4 cycles were needed until complete homogenization of the tissue. Then 0.2 ml of chloroform were added to homogeneized sample. After shaking and centrifuging for 12,000 x g for 15 minutes two phases formed; Aqueous fase was collected and transferred to a new tube.

RNA was afterwards cleaned by using QIA-GEN RNeasy columns following manufacturers’ directions. RNA purity was assessed by Nanodrop plots and agarose gel profile.

Isolated RNA was then handed to Genomic Unit in CNIC to proceed with sequentiation.

RNASeq. Data analysis

RNASeq library production

In order to assess the gene expression changes in iMOST1-Myc hearts upon mosaic Myc overexpression, total RNA was extracted from hearts induced to recombine with tamoxifen at t1, according to the scheme in figure 20.

Two hearts from iMOST1-Myc; My6-merCremer were used while two hearts from iMOST1-Myc littermates without Cre expression were used as control. RNA was isolated using standard procedures and analyzed using RNA-Seq. Total RNA was quantified by absorbance at 260 nm in a NanoDrop spectrophotometer and its integrity was determined using an Agilent Bioanalyzer (Santa Clara, CA).

Total RNA (1 µg) was used with the TruSeq RNA Sample Preparation v2 Kit (Illumina, San Diego, CA) to construct index-tagged cDNA libraries. The quality, quantity and the size distribution of the Illumina libraries were determined using the DNA-1000 Kit (Agilent Bioanalyzer).

Prepared cDNA libraries were applied to an Illumina flow cell for cluster generation (True Seq SR Cluster Kit V2 cBot) and sequence-by-synthesis single reads of 75 base length using the TruSeq SBS Kit v5 (Illumina) were generated on the Genome Analyzer Ix following the standard RNA sequencing protocol.
**RNASeq data analysis**

Sequencing adaptor contaminations were removed from reads using cutadapt software (http://code.google.com/p/cutadapt/) and the resulting reads were mapped and quantified on the transcriptome (Ensembl gene-build 70) using RSEM v1.2.3 (Li and Dewey, 2011).

Only genes with at least 2 counts per million in at least 1 sample were considered for statistical analysis. Data were then normalized and deferential expression tested using the bioconductor package EdgeR (Robinson et al., 2010). We considered as differentially expressed those genes with a Benjamini-Hochberg adjusted p-value ≤0.05.

Analysis of the data was performed using Gene set enrichment analysis and Ingenuity pathways analysis software (Biobase International).

**Image acquisition**

Images were acquired using a Nikon A1R confocal microscope using 405,458,488,568 and 633 nm wavelengths and 20x/0.75 dry and 40x/1.30 oil objectives. Tile scan, Z-stacks and large image acquisitions were performed using NIS software (version).

Acquisitions were commonly 1024x1024 px, A.U. set to 1 (except for adult cardiomyocyte imaging and Z-stacks steps as recommended by the optical configuration).

**Image analysis**

**Myc levels**

To quantify Myc protein expression ImageJ (http://rsb.info.nih.gov/ij) was used. Nuclei were detected by DAPI staining and segmented using threshold tool to create a mask.

When nuclei were too close, manual correction was applied to ensure segmentation detected only individual cells. Segmentation generated a mask that was used to measure mean intensity within the defined nucleus.

Mask was applied to Cy3 red channel staining (detecting Myc protein) and measure tool gave the mean intensity for every single object.

These intensity values were then classified into intervals and represented as interpolated curves derived from the original frequencies.

**EYFP/ECFP proportion**

EYFP/ECFP proportion was also quantified using ImageJ software. In cases when both EYFP and ECFP were clearly detected, both cell populations were quantified either by measuring the occupied area (using thresholding tool) for each cell type or counting cells (using cell counter plugin).

In those cases where ECFP was not detectable (in adults or neonate hearts), EYFP was quantified as previously mentioned and to estimate ECFP proportion, antiGFP staining was used to determine whole recombination.

**EYFP levels**

EYFP levels were quantified in adult isolated cardiomyocytes by determining cell area using threshold tool in ImageJ on a background channel. These areas were used to generate a mask that enabled to measure average intensity in EYFP channel. This was represented in arbitrary units. Values were classified into intervals and assigned to EYFP-negative, -medium or -high expression categories, which were defined identically for all experiments.

**Cell area**

Cell area was defined using ImageJ. Isolated adult cardiomyocytes’ area was measured using background green channel to detect objects and then ‘analyze particles’ tool from Image J to detect every cell as an object. Measure tool would give area for any given cell.

To measure area of cells stained with WGA (wheat germ agglutinin) on sections, Image J manual free hand selection was used.
3D Reconstructions
Z-stacks from embryonic hearts were reconstructed using Imaris x64 software. Imaris allowed to generate different isosurfaces (EYFP positive and negative cells) and detect those nuclei within isosurfaces.
A parameter ‘distance to EYFP’ was set to each TUNEL event and those within a cell diameter from a EYFP expressing cell where quantified as “in contact”.

Statistical analysis

To compare percentages of ECFP cells/area between more than two groups, Kurskall-Wallis test was used (assuming non-normal distributions).
For comparisons of two groups, Man-Whitney test was used. To test the correlation between cell size and EYFP expression levels, a linear regression model was used.
The significance of BrdU+ frequency and mononucleated cardiomyocyte frequency comparisons from adult hearts was analyzed using a proportions test as implemented in R.
All comparisons (and graphs) were made using Prism 5.0 statistical analysis software.
RESULTS

Knowledge is a treasure, but practice is key to it
(Lao Tzu)
Cell competition in the developing heart

Myc family expression in the developing heart.

To explore cell competition in the developing heart, we firstly addressed the role of Myc in the embryonic myocardium, as it has been shown to be a regulator of cell anabolism. Myc mRNA was not detected at E9.5 in the developing heart by in situ hybridization (ISH) (Figure 8 A, A'); as it had been previously reported. (Moens, Stanton et al. 1993).

We then decided to delete both Myc alleles in the developing heart to discard a role of Myc in myocardium development; and to do so we took advantage of Nkx2.5-Cre line to recombine Myc floxed alleles. Nkx2.5 is expressed in cardiac progenitors as early as E7.5 and Cre recombination takes place in myocardium derived from primary heart tube and from second heart field derivatives, as well as the endocardium and valve mesenchyme (Stanley et al. 2002).

Deletion of Myc gene using this driver did not produce any apparent cardiac embryonic phenotype (figure 8 B and C) and the proportion of adult cardiac-specific Myc knock-out animals was according to expected (figure 8 D). This result is in agreement with the expression pattern of Myc. We therefore focused on Mycn, a member of the Myc family expressed in the developing heart (figure 8 E, E'), specially in the compact layer of the myocardium (Davis et al. 1993,

Figure 8. Myc is dispensable for heart development

A. Whole mount in situ hybridization in E9.5 WT embryo for Myc, showing no expression of Myc in the developing heart (boxed area of A and A'). B. Whole mount image from a E10.5 WT embryo. C. Whole mount image from a E10.5 Myc flox/flox;Nkx2.5-Cre. D. Table showing the observed and expected proportion of adult animals from the three different genotypes: MycWT;Nkx-2.5; MycFlox/WT;Nkx2.5-Cre and MycFlox/Flox; Nkx2.5-Cre. E. Confocal section of a an E9.5 embryo (sagital view) showing Mycn immunodetection. E'. Magnification of the heart, from boxed area in E. F. Confocal section of a whole E10.5 right ventricle showing staining for Myc (upper panel) and Myc merged with DAPI (lower panel). Bar, 50 μm. H: Head, Hrt: Heart, RV: Right ventricle.
Moens, Stanton et al. 1993). It has been reported that nMyc deletion in the heart, using TnT-Cre (expressed specifically in cardiac myocytes) produces a defect in myocardium proliferation and does not yield live embryos past E12.5, with most of them being recovered alive only up to E11.5 (Harmelink et al. 2013). Interestingly, Myc and Mycn proteins are very similar and are able to functionally replace each other in mice in which Mycn has been knocked-in replacing endogenous Myc (Malynn et al. 2000). Myc overexpression through the iMOS system should therefore be functionally equivalent to Mycn expression, recapitulating and contributing to its function in the developing myocardium.

Moreover, using anti-Myc antibodies in wild-type, heterozygous and knock-out embryos, nuclear signal was still detected in the myocardium, indicating that the antibody also recognizes Mycn expression in the myocardium (figure 8 F).

**Generation of random genetic mosaics in the developing heart through the iMOS system. Overexpression of Myc under the Rosa26 promoter**

To study cell competition in the developing heart we used Nkx2.5-Cre to induce iMOS recombination in early cardiac progenitors. This approach is expected to generate random mosaics in cardiac lineages during development.

We first generated mosaics recombining the iMOSWT transgene, which gives rise to
random mosaics of ECFP- and EYFP-WT cell populations.

Quantitative confocal analysis of recombination at E10.5 in iMOS\textsuperscript{WT};Nkx2.5-Cre hearts confirmed the mosaic expression pattern of the two reporter proteins in embryonic cardiomyocytes at a reproducible cell population ratio, as previously described (EYFP:ECFP = 3:1) (Claveria et al. 2013) (figure 9 A-C, G, H).

As had been shown for the Nkx2.5-Cre line (Stanley et al., 2002), the fluorescent protein distribution pattern showed iMOS activation throughout the embryonic heart (figure 9 A-C).

We then generated Nkx2.5-Cre-induced iMOS\textsuperscript{T1-Myc} mosaics, in which the EYFP cell population moderately overexpresses Myc under the Rosa26 promoter (see methods figure 6) (Figure 9 D-F').

To address functional Myc overexpression we analyzed Myc protein levels through immunodetection on confocal sections in both mosaics. This analysis showed that Myc levels in iMOS\textsuperscript{WT} mosaics were comparable between the two mosaic populations; and, in contrast to what had been observed in the epiblast in the context of endogenous cell competition (Claveria et al. 2013), levels were cell-to-cell homogeneous. In the EYFP cell population of iMOS\textsuperscript{T1-Myc} mosaic hearts an expected increase in Myc expression levels in the EYFP cell population was observed (figure 9 I, J).

This increase is attributable presumably to the simultaneous detection by the antibody of exogenous Myc and endogenous Mycn.

**Mosaic Myc overexpression induces cardiomyocyte population expansion in the developing heart**

To test the effect of Myc overexpression in a mosaic fashion during heart development, we analyzed neonatal hearts from iMOS\textsuperscript{WT} and iMOS\textsuperscript{T1-Myc} mosaics. Confocal analysis showed a strong reduction of the ECFP-WT cell population in iMOS\textsuperscript{T1-Myc} mosaics, where these cells are confronted with Myc overexpressing ones.

At birth, the contribution of WT cardiomyocytes in iMOS\textsuperscript{T1-Myc} mosaics had dropped to 25% of its original contribution to the heart (figure 10 A, B, D, E and G).

To understand the temporal dynamics of the shift in the contribution of the EYFP-Myc and ECFP-WT cell populations, we quantified by confocal analysis the contribution of the mosaic cell populations at different stages of the developing heart, using again Nkx2.5-Cre to induce the iMOS system.

In iMOS\textsuperscript{T1-Myc} mosaics we found a progressive reduction in the contribution of the ECFP-WT cell population (and a correlatively increased contribution of the EYFP-
Myc population) that was not observed in the

The reduction in the proportion of ECFP-WT cardiomyocytes in iMOSWT mosaic hearts compared with iMOSWT hearts was detected already at E9.5, although this decrease was not found to be significant.

However, from this developmental stage on, the contribution of ECFP-WT population in iMOST1-Myc mosaic hearts was progressively reduced during development, with elimination of 75% of the normal ECFP-WT population contribution at birth. The reduction was 40% of the iMOSWT value at E10.5, 60% at E11.5 and 75% at P0 (figure 11 G).

This indicates that the shift in cell populations probably takes place constantly during the period observed but it does so more intensely in a two-day window between E9.5 and E11.5.

**Mosaic Myc overexpression in the embryonic heart provokes no pathological hyperplasia of cardiomyocytes**

Previous studies showed that Myc overexpression in cardiomyocytes during fetal life can lead to pathological cardiac hyperplasia (Jackson et al., 1990).

However, in these studies Myc overexpression was 20-fold above normal. Myc-overexpression levels through the Rosa26 promoter had been shown to be mild in the quantitative analysis performed initially to test iMOS sys-

---

**Figure 10. Myc-overexpressing population shows an expansion at P0**

A-C. Confocal detection of EYFP+ and ECFP+ cardiomyocyte distributions in histological sections of the left ventricle of P0 hearts from Nkx2.5-Cre recombined iMOSWT (WT) (A), iMOST1-Myc (MYC) (B) and iMOST1-Myc/T2-p35 (MYC/p35) mice (C). Bar, 50 μm. D-F. show masks of the EYFP detection in A-C. G. Percentage of ECFP+ cells observed at P0 in whole hearts of the iMOST1-Myc (MYC) and iMOSWT (WT) mosaics relative to that observed in the iMOSWT (WT) mosaics, which was normalized to 100%. Data in G are means ±SEM; * p<0.05; ** p<0.01; *** p<0.001.
tem recombination (Claveria et al. 2013) and in agreement with the observations in early embryos, we find that Myc overexpression levels approximate to the addition of one WT Mycn copy in the heart (figure 9 J).

To determine whether this overexpression levels could lead to cardiac hyperplasia we characterized postnatal heart anatomy and cardiomyocyte size. P0 hearts from Nkx2.5-Cre-recombined iMOSWT (WT) (A-C) and iMOST1-Myc (MYC) (D-F) embryos. Bar, 50 μm. G. Percentage ECFP+ area at different embryonic stages in whole hearts of the iMOST1-Myc (MYC) mosaics relative to that observed in the iMOSWT (WT) mosaics, which was normalized to 100%. Numbers on the X-axis indicate the day of embryonic development; P0 indicates postnatal day 0 (N≥5 embryos). Data in G are means ±SEM; * p<0.05; **p<0.01; ***p<0.001.

RESULTS

Figure 11. Myc-overexpressing cardiomyocyte population expands in the developing heart

A-F. Confocal sections showing EYFP+ and ECFP+ cardiomyocyte distributions in the left ventricle of whole-mount E10.5 hearts from Nkx2.5Cre-recombined iMOSWT (WT) (A-C) and iMOST1-Myc (MYC) (D-F) embryos. Bar, 50 μm. G. Percentage ECFP+ area at different embryonic stages in whole hearts of the iMOSWT (WT) mosaics, which was normalized to 100%. Numbers on the X-axis indicate the day of embryonic development; P0 indicates postnatal day 0 (N≥5 embryos). Data in G are means ±SEM; * p<0.05; **p<0.01; ***p<0.001.

from expansion of the EYFP Myc-overexpressing cardiomyocyte population at the expense of the ECFP-WT population, without involving modifications in cardiomyocyte number or size or heart anatomy.

These results also indicate that the levels of Myc overexpression from the iMOST1-Myc allele through Rosa26 promoter are within the limits that allow normal cardiac development and cardiomyocyte function and do not lead to hyperplasia.
Islet1 progenitors are highly sensitive to Myc-induced cell competition

We then explored whether this expansion would take place in specific compartments of the developing heart; and to do so we took advantage of Islet1-Cre, to induce recombination in second heart field progenitors, since Islet1 is a specific marker of SHF derivatives (Yang et al. 2006).

We wanted to test whether Islet1+ second heart field progenitors were also sensitive to Myc-induced cell competition, and the impact of inducing mosaicism in this particular cell population.

To test this, we generated iMOS<sup>WT</sup> mosaics in the second heart field (SHF) using Islet1 to drive Cre expression. This driver provides partial interspersed recombination in the SHF population resulting in a 7% con-
tribution of EYFP cardiomyocytes to the right ventricle (RV) in the neonatal heart. (figure 13 A, E, E’).

Interestingly, Myc mosaic overexpression in this SHF population dramatically increased the contribution of EYFP-Myc cells to the RV, which was 40% of the RV at P0, which represents a 6-7-fold expansion of the original EYFP cardiomyocyte population during development (figure 13 B, D F, F’). Moreover, the ECFP-WT cardiomyocyte population was almost completely eliminated from the RV in iMOS1-Myc mosaic hearts, indicating a very active elimination of the ECFP-WT population and a continued expansion of the Myc-overexpressing cardiomyocyte popula-

![Image of EYFP cardiomyocytes](image)

Figure 13. Myc-overexpressing cardiomyocytes upon mosaic induction in Islet1+ progenitors show an enhanced expansion at P0

A-G’. Confocal detection of EYFP+ (A-C), anti-GFP immunofluorescence (detecting both EYFP and ECFP) (E-G) and co-localization of both signals (E’-G’) in histological sections from Islet1-Cre recombinated iMOSWT (WT) (A, E, E’), iMOS1-Myc (MYC) (B, F, F’), iMOS1-Myc/p35 (MYC/p35) newborn mice. In E’-G’, EYFP+ cells are yellow because they are positive for both EYFP and anti-GFP, and ECFP+ cells are detected in red, as they are only positive for anti-GFP. Bar, 100 µm for A to C and 50 µm for E’. RA: right atrium, LA: left atrium, RV: right ventricle; LV: left ventricle. D. Percentage of the RV area positive for anti-GFP immunofluorescence in Islet1Cre recombinated iMOSWT (WT), iMOS1-Myc (MYC) and iMOS1-Myc/p35 (MYC/p35) newborn mice (N=4). H. Percentage of ECFP-recombined area with respect to the total EYFP+ECFP-recombined area observed at P0 in the iMOS1-Myc (MYC) and iMOS1-Myc/p35 (MYC/p35) mosaics relative to that observed in the iMOSWT (WT) mosaics, which was normalized to 100% (N≥4). Data in D, H are means ±SEM. *p<0.05; **p<0.01; ***p<0.001.
tion during fetal life, in a context in which it is continuously confronted with WT cardiomyocytes (figure 13 H).

To further understand how this expansion takes place, we characterized the temporal progression of the ECFP-WT cardiomyocytes in \textit{iMOS}^{T1-Myc} mosaics; and found that as early as E9.5 this population is already decreased to 40% of its normal contribution in the \textit{iMOS}^{WT} mosaic; with a further progressive reduction until the near-complete elimination found at birth (figure 14 A-D).

This enhanced early elimination of ECFP-WT cells indicates that the undifferentiated Islet1 progenitors are especially sensitive to Myc mosaic overexpression.

**Cell proliferation does not account for the expansion of the Myc-overexpressing cardiomyocyte population**

We then studied which mechanisms could underlie Myc-overexpressing cardiomyocyte expansion; and firstly we addressed the role of cell proliferation in this process.

To do so, we performed Phosfohistone3 (PHH3) staining in E10.5 hearts, when the shift in the cell population is taking place. We determined the percentage of proliferating cells in both \textit{iMOS}^{WT} and \textit{iMOS}^{T1-Myc} mosaics relative to that observed in the \textit{iMOS}^{WT} (WT) mosaics, which was normalized to 100%. Numbers on the X-axis indicate the day of embryonic development; P0 indicates postnatal day 0 (N=4). Data in D are means ±SEM. *p<0.05; **p<0.01; ***p>0.001.

To confirm these observations, we also performed BrDU staining and results were similar, with no differences in BrDU+ cell frequency between \textit{iMOS}^{WT} and \textit{iMOS}^{T1-Myc} (figure 15 F-H) or between the EYFP-Myc and ECFP-WT populations of the \textit{iMOS}^{T1-Myc} mosaic hearts (figure 15 I-J).

These results fit with previous studies.

**RESULTS**

![Figure 14. Myc-overexpressing cardiomyocytes upon induction in Islet1 progenitors, show an early expansion](image)
Figure 15. Analysis of cell proliferation upon Myc mosaic overexpression in the developing heart

A, B. Z-projections from 30 μm confocal stacks obtained from E10.5 left ventricles of iMOS\textsuperscript{WT} (WT) and iMOS\textsuperscript{T1-Myc} (MYC) mosaics, showing anti PHH3 staining to mark cell division. Bar, 50 μm. C. Total PHH3 density measured as number of positive cells per arbitrary area units at E10.5 in iMOS\textsuperscript{WT} (WT) and iMOS\textsuperscript{T1-Myc} (MYC) mosaics (N=4 hearts, N\textsubscript{e}20 positive cells/heart). D. Confocal section of a MYC mosaic left ventricle at E10.5, showing the distribution of EYFP\+, ECFP\+ and PHH3\+ cells. Bar, 50 μm. E. PHH3\+ nuclei frequency in the EYFP and ECFP populations of iMOS\textsuperscript{T1-Myc} mosaics (N=5 embryos and ≥ 680 nuclei). The filled arrowhead marks an EYFP\+, PHH3\+ cell and the empty arrowhead, an ECFP\+, PHH3\+ cell. Data are means ± SEM.*p<0.1; **p<0.05; ***p<0.001. F,G. Confocal sections from E10.5 left ventricles of iMOS\textsuperscript{WT} (WT) and iMOS\textsuperscript{T1-Myc} (MYC) mosaics showing anti BrDU staining. H. BrDU\+ cardiomyocyte frequency analyzed at E10.5 in iMOS\textsuperscript{WT} (WT) and iMOS\textsuperscript{T1-Myc} (MYC) mosaics (N=4 hearts, N\textsubscript{e}20 positive cells/heart). I. Confocal section of an iMOS\textsuperscript{T1-Myc} mosaic (MYC) E10.5 left ventricle showing the distribution of EYFP\+ and BrDU\+ cells. I'. detailed image of the boxed area in I. J. BrDU\+cardiomyocyte frequency in the EYFP-Myc (MYC) and ECFP-WT (WT) populations of the iMOS\textsuperscript{T1-Myc} mosaic (N=4). Bar, 20μm. Filled arrowhead shows an EYFP\+, BrDU\+ cell and empty arrowhead, an ECFP\+, BrDU\+ cell. Data are mean ± SEM.*p<0.1; **p<0.05; ***p<0.001
showing that the Myc dosage induced by a single Rosa26 allele does not increase proliferation rates in most tissues (Claveria et al., 2013; Murphy et al., 2008) and indicate that differences in cell proliferation do not account for the shift in cardiomyocyte populations.

Myc-overexpressing cardiomyocyte population expands by apoptosis-driven cell competition

Then we decided to evaluate the role of apoptotic cell death in the depletion of WT
cardiomyocytes.

To do so, we generated a third mosaic line; \(iMOS^{T1-Myc/T2p35}\), which generates random mosaics upon recombination. In these mosaics, an ECFP-p35 cell population is confronted with an EYFP-Myc population.

P35 is a baculoviral caspase inhibitor that prevents apoptosis both in insects and mammals (Claveria et al., 2013, Hay et al., 1994).

Quantitative confocal analysis of neonatal hearts induced with \(Nkx2.5-Cre\) showed that these mosaics retained at birth 70% of the original p35-expressing ECFP cell (figure 10 C, F, G). This contrasts with the 25% of WT cells observed in \(iMOS^{WT}\) mosaics, indicating that apoptosis inhibition significantly, although not totally, preserved WT cells from elimination when confronted with Myc-overexpressing cells (figure 10 G).

We also tested generating \(iMOS^{T1-Myc/T2p35}\) mosaics using \(Islet1-Cre\) to analyze the behaviour of second heart field progenitors (figure 13 C, G, G'). We found, accordingly with the observations with \(Nkx2.5-Cre\) recombination, that the ECFP population is partially protected from elimination (figure 13H).

We found, however, that the expansion of the EYFP-Myc population was similar to that observed in \(iMOS^{T1-Myc}\) mosaics (figure 11D), indicating that the expansion of Myc-overexpressing cardiomyocytes takes place also by eliminating non-recombined WT cardiomyocytes, being not affected by the presence of a low proportion of ECFP-p35 cardiomyocytes.

These results indicate that cell death is a predominant mechanism in the population shift observed in \(iMOS^{T1-Myc}\) mosaics.

To further assess this, we performed TUNEL assays to score apoptotic rates in E10.5 mosaic hearts recombined using \(Nkx2.5-Cre\). We decided to focus mainly on the outflow tract region (OFT) since it was the one showing higher apoptotic rates in the \(iMOS^{WT}\) mosaics (figure 16 A, B).

While the proportion of TUNEL-positive cardiomyocytes was in general extremely low in \(iMOS^{WT}\) mosaics, we observed a 5-fold increase in the overall apoptotic rate in \(iMOS^{T1-Myc}\) mosaics (figure 16 C). Moreover, in \(iMOS^{T1-Myc}\) mosaics, the apoptotic rate in the ECFP-WT population was remarkably higher than that seen in the EYFP Myc population (figure 16 D-F).

Interestingly, the apoptosis rate varied between heart regions: whereas the ECFP/EYFP TUNEL ratio was 4 to 5-fold above baseline in the ventricles, in the OFT it was over 10-fold higher, indicating that ECFP-WT cardiomyocytes expand by inducing apoptosis of neighbouring WT cardiomyocytes.

Figure 16. Myc-overexpressing cardiomyocytes expand by inducing apoptosis of neighbouring WT cardiomyocytes

A, B. Maximal projections of confocal stacks (30 μm deep) from the OFT region of \(Nkx2.5-Cre\) recombined \(iMOS^{WT}\) (WT) (A) and \(iMOS^{T1-Myc}\) (MYC) (B) whole-mount TUNEL-stained E10.5 hearts. Bar, 50 μm. C. TUNEL staining frequency in cardiomyocytes from the mosaics shown in A, B (N = 4 WT and 7 MYC mosaics). D, E. Confocal sections from the LV of \(Nkx2.5-Cre\) recombined \(iMOS^{WT}\) (WT) (D) and \(iMOS^{T1-Myc}\) (MYC) (E) Whole-mount TUNEL-stained E10.5 hearts, showing overlaid EYFP, ECFP and TUNEL signals. Filled arrowheads point to EYFP+ TUNEL+ cells and empty arrowheads to ECFP+ TUNEL+ cells. Bar, 50 μm. F. ECFP/EYFP TUNEL frequency ratios in different regions of \(Nkx2.5-Cre\) recombined \(iMOS^{WT}\) (WT) and \(iMOS^{T1-Myc}\) (MYC) whole-mount E10.5 hearts (N = 4 WT and 7 MYC mosaics). LV, left ventricle; RV, right ventricle; OFT, outflow tract. Arrowhead marks the unbiased ECFP/EYFP TUNEL frequency ratio = 1. G. Maximal projection of the OFT from an \(Islet1-Cre\) recombined \(iMOS^{T1-Myc}\) E10.5 heart (MYC), showing overlaid EYFP, DAPI and TUNEL signals. Bar, 70 μm. H. Computer 3D reconstruction of the stack shown in G. H'. Magnification of the boxed region in H, showing TUNEL+ WT cells contacting (red) and not contacting (light blue, arrowhead) MYC-overexpressing cells. Bar, 20 μm. **I TUNEL frequency in WT cells contacting and not contacting EYFP cells in Isn1Cre- recombined iMOS1-Myc E10.5 hearts (MYC) (N=3 and ≥ 2815 cells). Data in C, F, I are means ±SEM. **p<0.01; ***p<0.001.
cardiomyocytes in this region are especially sensitive to mosaic Myc overexpression (figure 16 F).

**Competition induced apoptosis relies on short range interactions**

Since ECFP-WT cells are normal viable cells, our results suggested that a cell-non autonomous mechanism was involved in their increased death rates.

We therefore studied the spatial range of these interactions of these interactions. To do so, we took advantage of the low-rate, interspersed recombination generated in the OFT region by the Islet1-Cre driver. This way, we generated a mosaic in which a few EYFP cells would lie within an excess of WT cells, allowing us to score apoptosis separately in WT cells in direct contact with EYFP-Myc cells and in those not in contact (figure 16 G-H').

Apoptotic rate was found to be highly increased only in those WT cardiomyocytes that were in direct contact with Myc-overexpressing EYFP cardiomyocytes. Specifically, we found a 17-fold increase in apoptosis in WT contacting cardiomyocytes compared to WT non-contacting cardiomyocytes (figure 16 I).

Therefore, these results indicate that the expansion of Myc-overexpressing cardiomyocytes that were in direct contact with Myc-overexpressing EYFP cardiomyocytes. Specifically, we found a 17-fold increase in apoptosis in WT contacting cardiomyocytes compared to WT non-contacting cardiomyocytes (figure 16 I).

Flower protein has been previously proposed to be implicated in cell competition in *Drosophila* through the expression of different protein isoforms that allow cells to communicate each others’ fitness.

To determine whether *Flower* plays a role in induced cell competition in the developing heart, we generated *iMOST1-Myc* mosaics using Nkx2.5-Cre recombination in a *Flower* knockout background (*Flower* knock-outs have been described to be fertile, viable and to display a reduced incidence of papilloma formation) (Petrova et al., 2012).

Analysis of confocal sections showed that ECFP-WT cell elimination in *iMOST1-Myc* mosaics was similar in WT, heterozygous and homozygous *Flower* knockout backgrounds (figure 17 A-D).

This indicates that, in this cell competition model, Flower activity is dispensable for the elimination of WT cells. Moreover we were unable to detect *Flower* expression in the heart by ISH (figure 17 E).

**Endogenous cell competition does not play a role in the developing heart**

Our results indicate that cardiac cells, including cardiomyocytes, are sensitive to induced cell competition.

These results however do not address whether endogenous cell competition could play a substantial physiological role in cardiac development. To test this, we generated a mouse mosaic strain in which EYFP labelled cells were WT (EYFP-WT) and ECFP labelled cells expressed p35 (ECFP-p35) cells.

This line, *iMOS*{superscript}p35, was recombined using *Mef2C-AHF-Cre*, which recombines the anterior region of the second heart field, since
this is the population that we have found to be more sensitive to cell competition.

In case endogenous cell death would be eliminating a substantial number of cardiac precursors, we would expect a significant enrichment in the proportion of ECFP-p35 cells.

In addition, in the case that these cells would have been eliminated by Myc-regulated cell competition, we would expect the ECFP-p35 cell population to express lower Myc levels than the EYFP-WT population. We then measured Myc protein levels in the ECFP-p35 population, in which apoptosis had been blocked (figure 18 A-D).

Analysis of Myc levels by immunodetection showed no differences between the EYFP-WT population and the ECFP-p35 population (protected from elimination), indicating that a mechanism for endogenous cell competition dependent on Myc levels is not present in the developing heart; since rescued cells
Mycn and Myc levels interplay in cell competition in the developing heart

We then explored whether modifying the relative differences in Myc dose between neighbouring cells affected the competition process.

To study this question, we manipulated Mycn levels in the myocardium by conditional elimination and combined this elimination with recombined \textit{iMOS} \textsuperscript{T1-Myc} mosaics (figure 19 A-C). We found that when EYFP-Myc cells were generated in a Mycn heterozygous

**RESULTS**

![Image of confocal imaging and EYFP-ECFP distribution](image)

**Figure 18.** p35 rescued cells do not show a decrease in their Myc levels

\textbf{A.} Confocal image showing a histological section from a E9.5 \textit{iMOS} \textsuperscript{T2-p35}; AHF-\textit{Mef2C} (p35; AHF-Cre) embryo, showing EYFP, ECFP and Myc immunostaining. \textbf{B.} Binary mask of DAPI staining corresponding to \textbf{A}. \textbf{C.} Binary mask of the nuclei corresponding to EYFP cells. \textbf{D.} Binary mask of the nuclei corresponding to ECFP cells. \textbf{D.} Distribution of Myc protein levels in the EYFP-WT and ECFP-p35 cell populations of \textit{iMOS} \textsuperscript{T2-p35}. Myc protein levels were quantified from the immunofluorescence images similar to those in \textbf{A}. (N=4). Dashed vertical lines indicate the mean for each distribution.
background, ECFP-Mycn +/- cells were depleted to a similar extent than that found in a WT background (figure 19 B, D).

Hence, confronting cells with the equivalent to two doses of Myc function with cells with one dose also eliminates those with lower relative Myc levels.

Moreover, ECFP-Mycn null cells were drastically reduced to 15% of the initial ECFP proportion when confronted with EYFP cells expressing a single Myc dose at stage E10.5 (Figure 19 C, D).

These results show that it is not the absolute level of Myc expression but the relative differences between cell populations, what triggers the elimination of those with relative low Myc levels.
Myc induced competition during adult heart homeostasis

Myc-overexpression in the adult heart causes no pathological alteration neither in homeostatic conditions nor in intense exercise conditions

Once we had determined that cell competition could be induced in embryonic cardiomyocytes during heart development, we then explored if an organ such as the adult heart could also be sensitive to Myc-induced cell competition.

To test this, we generated mosaic mouse lines in the adult heart taking advantage of the tamoxifen-inducible My6-merCremer strain (Sohal et al., 2001) (figure 20 A). We followed the protocol of induction shown in figure 20 A; in which induction was achieved through the diet, feeding the animals a tamoxifen diet for 1 month, starting right after weaning.

This protocol yields an initial EYFP recombination rate slightly above 50% (figure 21A). Since previous studies have reported that high Myc overexpression in cardiomyocytes of adult mice induces cardiomyocyte hypertrophy (Xiao et al., 2001), we performed a series of assays to address if this could be the case when we overexpress Myc moderately through the iMOS system in a long-term fashion.

Hearts from animals generated using the protocol previously described (figure 20 A) were tested for hypertrophic response. Firstly, we analyzed heart function and anatomy in iMOSWT and iMOS+Myc mosaics through echocardiographic study in basal conditions.

This study did not detect any differences between the mosaics studied (figure 20 B, C, D) in any parameter analyzed, neither anatomical nor functional; including ejection fraction and left ventricular mass.

We then studied whether challenging heart function following a protocol of intense exercise could trigger differences between iMOSWT and iMOS+Myc animals. We set up a swimming protocol that lasted for two months and that got the animals to swim for up to 90 minutes everyday (see methods: table 2).

Echocardiographic assays performed right after the protocol and one month after finishing showed again no differences in any of the parameters analyzed, regarding heart anatomy or function (figure 20 C, D right panels).

Even though hearts were not altered macroscopically (figure 20 E), we analyzed cardiomyocyte size to determine the consequences of long-term Myc overexpression. Measurement of average cardiomyocyte 2D-size, both in histological sections and incultures of disaggregated cardiac cells (fi-

Figure 20. Mosaic Myc overexpression in adult cardiomyocytes is phenotypically silent

A. My6-merCremer recombined iMOS12-Myc mosaics and control littermates were treated as schematized for experiments in B. B. Long axis M-mode echocardiography image from an iMOS12-Myc (MYC) mosaic WT littermate at t2. Graphs (C) show ejection fraction (EF) and left ventricle (LV) mass from the echocardiographic study, and heart/body weight ratios (E) in the iMOS12-Myc mosaics (MYC) and in WT littermates (WT) at t3 (N=3). D. Shows EF and LV mass at t2 after a protocol of intense exercise from t0 to t2 (see experimental procedures). F. G. Confocal sections showing wheat germ agglutinin (WGA) staining to highlight cell perimeters in iMOSWT (WT) (F) and iMOS12-Myc (MYC) (G) mosaics at t3. Bar, 50 μm. H, I. Brightfield confocal section of cardiomyocytes isolated from iMOSWT (WT) (H) and iMOS12-Myc (MYC) (I) mosaic hearts at t3. Bar, 50 μm. J. Size (2D area) of cardiomyocytes shown in H, I. (N≥4 hearts and 236 cells).*p<0.1; **p<0.05; ***p<0.001. Horizontal bars represent mean values. K, L. EYFP fluorescence intensity plotted against cell size for cardiomyocytes isolated from iMOSWT (WT) (K) and iMOS12-Myc (MYC) (L) mosaics. Lines in K and L represent the regression line (R-square = 2.040±5 and 0.007204, respectively).
#### RESULTS

**A**

- TAMOXIFEN
- BIRTH
- 1 MONTH
- 1 MONTH
- 1 MONTH
- 10 MONTHS
- t0
- t1
- t2
- t3

**B**

- WT
- MYC

**C**

- EF (%)
- ns
- LV mass (mg)
- ns

**D**

- EF (%)
- ns
- LV mass (mg)
- ns

**E**

- Heart/Body weight (mg/g)
- ns

**F**

- WT
- MYC

**G**

- WGA

**H**

- BRIGHTFIELD

**I**

- WT
- MYC

**J**

- Area (px²)

**K**

- Area (px²)
- Fluorescence intensity (a.u.)

**L**

- Area (px²)
- Fluorescence intensity (a.u.)
Figure 20 F-I), showed that cardiomyocytes in \(iMOS^{T1-Myc}\) hearts were not only not bigger than those in \(iMOS^{WT}\) hearts, but were in fact slightly smaller (figure 20 J).

Moreover, we also measured the correlation between Myc levels and cell size: since recombination occurs after binucleation, adult cardiomyocytes could contain more than one recombined EYFP-Myc copy and therefore are predicted to express variable levels of extra Myc in correlation with EYFP levels.

In \(iMOS^{T1-Myc}\) mosaics EYFP levels correlate with the Myc dose. Analysis of per-cell cardiomyocyte size and EYFP level showed no correlation between these two parameters in either \(iMOS^{WT}\) or \(iMOS^{T1-Myc}\) mosaic hearts (figure 20 K, L), indicating that Myc expression in our system has no direct effect over cell size.

These results show that sustained Myc overexpression from the \(iMOS^{T1-Myc}\) allele during adult life does not provoke cardiomyocyte hypertrophy. Heart size and heart/body weight ratios were moreover similar in both mosaics, indicating that overall cardiac cellular and organ anatomy are preserved (figure 20 E).
Myc overexpression induces cardiomyocyte population expansion in the adult heart

Once we had established the lack of pathological response due to Myc mild overexpression, we proceeded to determine the proportions of cardiomyocyte populations at different times after mosaic induction.

While in iMOSWT hearts the proportion of EYFP cardiomyocytes did not increase during aging and was 53% at 1 year of age (figure 21A, D), in the iMOST1-Myc mosaics the proportion increased progressively from a frequency similar to that found in iMOSWT hearts to 66% at 1 year of age (figure 21 B, D).

Interestingly, half of this enrichment took place during the first month of observation. Since there were no major changes in heart mass or cardiomyocyte size (figure 21 E, J), these observations suggest that Myc-overexpressing cardiomyocytes expand at the expense of WT cardiomyocytes during adult life.

To directly test this, we determined the relative frequency of ECFP cardiomyocytes with respect to all fluorescent (ECFP+EYFP) cardiomyocytes in 1-year-old iMOST1-Myc and iMOSWT mosaics (figure 21 E-H).

The ECFP cell frequency was ~60% lower in the iMOST1-Myc mosaics, confirming that the expansion of the Myc-overexpressing cardiomyocyte population is concomitant with a reduction in the WT population.

Since we had detected differences in Myc levels due to ploidy and nucleation of cardiomyocytes (most adult cardiomyocytes in the mouse are tetraploid and contain two nuclei (Soonpaa et al., 1996); together with the partial recombination achieved by tamoxifen treatment, we had generated heterogeneous levels of EYFP-Myc content in cardiomyocytes, with a predicted predominance of cardiomyocytes with one or two active EYFP-Myc copies.

We therefore refined our study to determine whether cardiomyocyte population expansion correlated with EYFP-Myc levels.

Fluorescence was measured in isolated cardiomyocytes and the frequency of cells according to fluorescence intensity was determined (figure 21 I). This analysis showed that the enrichment in EYFP+ cardiomyocytes in iMOST1-Myc mosaics mostly affects the populations with higher EYFP levels at the expense of EYFP-negative cardiomyocytes.
cytes, whose frequency decreased (figure 19 I). These observations indicate a correlation between Myc dose levels and cardiomyocyte population prevalence in the adult myocardium.

Analysis of the pathways involved in adult cardiomyocyte competition

To identify the pathways altered in the iMOS\textsuperscript{T1-Myc} adult mosaic heart, we performed a transcriptomic analysis by RNA-seq, com-

![Gene expression heatmap](image)

**B.** Ingenuity Pathway Analysis (UP and Down genes)

<table>
<thead>
<tr>
<th>Enriched Functional Gene Classes (all genes)</th>
<th>Upregulated</th>
<th>Downregulated</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inflammation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIOCARTA_MONOCYTE_PATHWAY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIOCARTA_COMP_PATHWAY (complement pathway)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Response to Cardiac Overload</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIOCARTA_ALK_PATHWAY (Fetal cardiomyocyte program)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIOCARTA_MET_PATHWAY (Signaling of Hepatocyte Growth Factor Receptor)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIOCARTA_RHO_PATHWAY (Rho cell-motility signaling pathway)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOBP_TISSUE_REMODELING</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Metabolic Pathways</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEGG_CIRCadian_Rhythm_MAXIMAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Circadian Rhythm Regulation)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEGG_PEROXISOME</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Peroxisome biogenesis and function)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOBP_RRNA_MetABOLIC_PROCESS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Ribosome Biogenesis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEGG_LYSOSOME</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Lysosome assembly and function)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GOBP_UPASE_ACTIVITY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Lipid catalysis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GOBP_APOPTOTIC_PROGRAM</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**RESULTS**

Figure 22. Transcriptomic analysis of the changes induced by Myc mosaic overexpression in the adult heart. Ingenuity pathway analysis

A representation of the list of genes up- or down-regulated in iMOS\textsuperscript{T1-Myc} mosaics with respect to controls and their expression levels. Criteria for inclusion were adjusted p-values<0.05 and expression levels ≥10 counts/million reads in at least one condition. Genes are colour-coded for involvement in predominant known functional classes for this gene set (see legend). B. top table; significant (p<0.05) gene sets enriched in up- or down-regulated genes, including all genes in the analysis. Lower table; Top Ingenuity pathways and networks detected in the gene set shown in A (p<0.01). Pathways include those detected in the independent analysis of the upregulated and downregulated genes and in their joint analysis.
paring 8-week old $iMOS^{T1-Myc}$ and control hearts (figure 22).

Among the genes more significantly up or downregulated in $iMOS^{T1-Myc}$ hearts there is a strong representation of genes involved in the response to cardiac overload, in cell growth/division, in energy metabolism and in apoptosis (figure 22 A).

Gene set enrichment analysis on all genes present in the RNAseq experiment again detected the protective response to cardiac overload in $iMOS^{T1-Myc}$ hearts, including the activation of the atrial natriuretic peptide and fetal cardiomyocyte programs (Kishimoto et al., 2001) (Kuhn et al., 2002) and the HGF/Rho/Tissue remodeling pathways (Madonna et al., 2012).

In contrast, the EGF pathway, involved in the development of pathological hypertrophy (Shah and Catt, 2003) was found repressed in $iMOS^{T1-Myc}$ hearts.

Regarding metabolic processes, activation of the ribosome biosynthesis, a typical response to Myc overexpression, was also detected. In parallel, activation of the lysosomal pathway was as well present, indicating that metabolic activity was globally increased including both anabolic and catabolic processes.

With regard to the metabolic processes, $iMOS^{T1-Myc}$ hearts showed a reduction in lipid catabolism and in assembly of the peroxisome, the main organelle for lipid catabolism, suggesting a modification in the fuel usage by Myc-overexpressing cardiomyocytes.

A remarkable alteration was found in various regulators of the circadian rhythm; $Dbp$ and $Per1$, 2 and 3 were upregulated and $Arntl$ ($Bmal1$) was downregulated. Circadian rhythm transcription factors are essential regulators of cardiac metabolism, regulate the balance between lipid and glucose usage in the heart and display a feedback regulation with the oxidative phosphorylation pathway (Durgan and Parker, 2010).

A major regulator of cardiac metabolism, AMPK, has also been described to undergo circadian regulation (Tsai et al., 2010) its
regulatory subunit is overexpressed in the iMOS\textsuperscript{T1-Myc} hearts, and it can be activated by Myc overexpression (Nieminen et al., 2013). The results observed are therefore compatible with a modified metabolic status of the iMOS\textsuperscript{T1-Myc} with either a direct or indirect impact of Myc overexpression on the circadian metabolic regulation.

In agreement with this view, the Ingenuity Pathway analysis on the selected up- and down-regulated genes (figure 22 B) indicates a modification of the Lipid metabolism and a reduction of the Oxidative Phosphorylation activity in iMOS\textsuperscript{T1-Myc} hearts. The top networks identified by this analysis for the upregulated, the downregulated and the joint gene sets are again the networks activated in response to cardiac overload (figure 22 B, 23A-C). In agreement with these results we found that the expression of the atrial natriuretic peptide was clearly activated in a patchy pattern in the ventricles of the iMOS\textsuperscript{T1-Myc} mosaic hearts (figure 24A-B').

Given the known functions of Myc in cardiomyocytes, the pathways detected likely result from cell-autonomous Myc functions and may relate to the ability of Myc-overexpressing cardiomyocytes to replace the WT cardiomyocyte population.

In addition, the Gene Set Enrichment study identified the activation of the apoptosis regulation and inflammation pathways in iMOS\textsuperscript{T1-Myc} hearts, which could be related to the death and removal of WT cardiomyocytes. We therefore used the iMOS\textsuperscript{T1-Myc/72p35} mosaics to undertake a functional study of the involvement of cell death.

This analysis showed that p35 expression largely rescues the ECFP cell population (figure 21 C, G, H).

These results indicate that adult cardiomyocytes undergo Myc-induced cell competition, which progresses by elimination of WT cardiomyocytes and their replacement by cardiomyocytes with high Myc levels.

We then analyzed whether increased proliferation of the Myc-overexpressing population is contributing to this phenomenon. We found that BrdU incorporation was 4-fold more frequent in the EYFP-Myc cardio-

Figure 24. Nppa is upregulated in iMOS\textsuperscript{T1-Myc} mosaic

A. Expression analysis of Nppa protein in adult iMOS\textsuperscript{WT} (WT) B. iMOS\textsuperscript{T1-Myc} (MYC) mosaics. A and B panels show low magnification images of immunofluorescence detection of Nppa and boxed areas are magnified in the bottom A' and B' panels. RA, right atrium, RV, right ventricle. Bars, 100\textmu m top; 50\textmu m bottom.
myocytes than in the WT cardiomyocytes of iMOS\textsuperscript{T1-Myc} mosaic hearts (figure 25 A, B). This increase did not alter the proportion of mononucleated cardiomyocytes (figure 25 C), suggesting that the balance between mononucleated cardiomyocyte division and binucleation is preserved.

To directly assess the involvement of apoptosis in the cardiomyocyte population shift, we analyzed the TUNEL pattern in adult iMOS\textsuperscript{T1-Myc} mosaics, however, we found no significant differences in TUNEL frequency between the EYFP-Myc and ECFP-WT cell populations.

These results suggested that, unlike the situation during development, apoptosis might not be involved in the elimination of WT cardiomyocytes in adults, despite the activation of apoptotic pathways detected by RNAseq.

We then explored whether alternative cell death pathways could be operating in postnatal cardiomyocytes.

Given that p35, in addition to inhibiting apoptotic cell death, can also inhibit autophagic cell death (Martin and Baehrecke, 2004) and that many apoptosis regulators are also involved in autophagic cell death, we tested whether this pathway could be involved in postnatal cardiomyocyte cell competition.

Analysis of the autophagic death-specific marker Beclin (Liang et al., 1999) showed rare positive cells in iMOS\textsuperscript{WT} hearts (figure 26 A, A', A''), however the frequency of Beclin-positive cells increased by 5-fold in iMOS\textsuperscript{T1-Myc} mosaic hearts (figure 26 B, B', B'', C).

Moreover, the frequency of Beclin-positive cells within the iMOS\textsuperscript{T1-Myc} mosaics was 9-fold higher in ECFP-WT cells than in EYFP-Myc
These results indicate that autophagic cell death instead of apoptotic cell death is a major contributor to postnatal cardiomyocyte cell competition.
Cell competition in the developing epicardium

Myc overexpression increases the contribution of Wt1 lineage to the heart during development

Having induced cell competition in the cardiomyocyte lineage during heart development, we decided to test the potential of cell competition in the developing epicardium.

The epicardium gives rise to different cell types during heart development (Wessels and Perez-Pomares, 2004) and has risen a lot of attention as a possible source of progenitors to replenish smooth muscle cells and myocardium, both during development and in the adult heart upon injury (Smart et al., 2011, Smart et al., 2007, Zhou et al., 2008).

To explore the roles of Cell Competition in epicardium, we recombined either iMOS\textsuperscript{WT} or iMOS\textsuperscript{TI-Myc} transgenes using Wt1-Cre.

Analysis of histological sections at E14.5 in the iMOS\textsuperscript{WT} heart showed the described contribution of the Wt1 lineage to the myocardium. We found contribution to the epicardial layer and to epicardial derived cells (EPDCs) as well as to a few cardiomyocytes that appear scattered in the inter-ventricular septum (Wessels et al., 2012)(figure 27 A, A').

In contrast, histological sections from E14.5 iMOS\textsuperscript{TI-Myc} hearts showed a remarkable contribution to both ventricles and the inter-ventricular septum (IVS) of the Wt1-Cre lineage (figure 27 B, B').

Quantification of the recombined area showed a four to five-fold increase in the contribution of Wt1 lineage to the ventricles and the IVS at E14.5 (figure 25 E-G).

This contribution progressed until birth when the proportion of the Wt1-Cre lineage to the ventricles raised to 50% of the total ventricle area (figure 27 C-D' and E,G), whereas the increase in the area of contribution to the IVS was lower (figure 27 G).

Myc overexpression in the Wt1-Cre lineage promotes preferential colonization of epicardium, EPDCs and Ventricular Cardiomyocyte populations.

To determine the contribution of EYFP-Myc cells from the Wt1-Cre lineage at E14.5, we performed flow cytometry analysis of whole E14.5 iMOS\textsuperscript{WT} and iMOS\textsuperscript{TI-Myc} hearts.

Quantification of these assays showed a doubling in the EYFP population proportion in iMOS\textsuperscript{TI-Myc} hearts compared with that observed in iMOS\textsuperscript{WT} hearts (figure 28 A-C).

We detected that the increase in the area of contribution of Wt1-Cre lineage was mostly due to a contribution to the cardiomyocyte population (figure 29 A-B').

To further determine the effect of Myc overexpression on the Wt1-Cre lineage in the different cell populations, we quantified the relative proportion of EYFP cells with respect to the total recombination (EYFP+ECFP) in histological sections in non-cardiomyocyte (mostly EPDCs and epicardial cells) and in cardiomyocyte cell populations from the free walls of both ventricles (VFW) and the IVS.

In both left and right VFWs and in the IVS, we detected a homogeneous enrichment (as an increase in the EYFP/ECFP ratio) in EYFP-Myc cells in the non-cardiomyocyte fraction of around 10-15% in iMOS\textsuperscript{TI-Myc} versus iMOS\textsuperscript{WT} hearts (figure 29 C-E). Moreover, in histological sections we detected that the coronary perivascular cell population was composed 100% of EYFP-Myc cells in iMOS\textsuperscript{TI-Myc} hearts (figure 30 A-C), indicating a competitive advantage of Myc-overexpressing EPDCs in colonizing the perivascular niche and differentiating to smooth
**Figure 27. Myc overexpression enhances Wt1 lineage contribution to the developing heart**

A-B’. Confocal images from histological sections of iMOS<sup>WT</sup> (WT) (A) and iMOS<sup>T1-Myc</sup> (MYC) (B) hearts at E14.5 induced with Wt1-Cre. A’ and B’ show magnification of the boxed areas shown in A and B. C-D’. Confocal images from histological sections of P0 iMOS<sup>WT</sup> (WT) (C) and iMOS<sup>T1-Myc</sup> (MYC) (D) recombined with Wt1-Cre. C’ and D’ show magnification of the boxed areas shown in C and D. E-F. Quantification of the percentage of recombined area detected in iMOS<sup>WT</sup> (WT) and iMOS<sup>T1-Myc</sup> (MYC) at E14.5 and P0 in the RV (E), IVS (F) and LV (G). Graphs in E, F, G show means ± SEM. *p<0.1; **p<0.05; ***p<0.001. Bar, 200 μm in A, B, C, D and 50 in A’, B’, C’, D’ ≥ 5 hearts.
muscle cells.

As mentioned before, we detected no EYFP or ECFP cells in the iMOSWT in either of the VFWs (ventricular free walls) (figure 29 C-E).

In agreement, all contribution of the Wt1-Cre lineage to the VFW cardiomyocyte population in iMOST1-Myc hearts was 100% from EYFP+ Myc-overexpressing cells. (figure 29 C, E). An important enrichment in the EYFP/ECFP ratio was also detected in the IVS cardiomyocyte fraction in iMOST1-Myc (figure 29 D).

These results indicate that Myc overexpression promotes preferential expansion cells derived from the epicardium and EPDCs, both known derivatives of the Wt1-Cre lineage. In addition, we found that Myc overexpression drives a strong contribution of the WT1-Cre lineage to the cardiomyocyte population, especially that of the VFWs.

Myc overexpression promotes the invasive behaviour of epicardial cells

To further understand the effect of Myc overexpression in epicardial cells, we set up a new ex-vivo system of epicardium-cardiomyocardium co-explants. This system allows us to understand epicardial behaviour when in presence of myocardium and myocardial signals, and represents an ex-vivo way of understanding epicardium-cardiomyocardium cross-talk.

We performed co-explant assays of E10.5 left ventricles (covered by epicardium) from iMOSWT and iMOST1-Myc mosaics confronting them with E9.5 WT left ventricles (not yet covered by epicardium), and cultured them for 24 hours.

We detected that epicardial cells form both iMOSWT and iMOST1-Myc E10.5 LVs were able to expand, migrate and reach the surface of the E9.5 WT myocardium. While iMOSWT epicardial cells remained on the myocardial surface (figure 31 A), in contrast, iMOST1-Myc epicardial cells invaded the WT myocardium.
Figure 29. Myc-induced Cell Competition takes place in epicardium and Epicardium derived cells. Myc overexpression promotes contribution of Wt1 lineage to the developing myocardium

A-B’. Confocal images from histological sections of iMOSWT (WT) (A) and iMOS12-Myc (MYC) (B) hearts at E14.5 induced with Wt1-Cre. A’ and B’ show amplified regions from boxed areas in A and B. C-E Percentage of EYFP+ cells observed at E14.5 in whole hearts of the iMOS12-Myc (MYC) and iMOSWT (WT) mosaics in the non cardiomyocytic fraction and in the cardiomyocyte fraction in the RV (C), IVS (D) and LV (E). Data are means ±SEM; * p<0.05; **p<0.01; ***p<0.001. n≥5 hearts. Bar, 200 μm in A,B and 50 in A’,B’

Figure 30. Contribution of EYFP-Myc cells to Smooth muscle lineage is enhanced

A-C. Confocal image from histological sections of P0 iMOS12-Myc hearts; showing EYFP (A), anti-GFP staining (B) and a merged image showing both channels (C). Bar, 50 μm. Filled arrowhead points to smooth muscle layer contribution to coronaries. Empty arrowhead points to a ECFP EPDC.
Figure 31. Coculture assays show enhanced invasiveness in $iMOS^{T1-Myc; Wt1-Cre}$ epicardium

A. Coculture from $iMOS^{WT}$ (WT) (A) and $iMOS^{T1-My}$ (MYC) (B) E 10.5 epicardium and a WT E9.0 heart, image showing EYFP and Brightfield. C. Maximum intensity projection of a Coculture of $iMOS^{WT}$ (WT) E10.5 epicardium and a WT E9.0 heart stained for c-TnT (Z=36 μm). D. Coculture of $iMOS^{T1-My}$ (MYC) E10.5 epicardium and a WT E9.0 heart stained for c-TnT (Z=36 μm). Dashed lines mark the outline of both explants, where (*) marks the WT heart and (E) is the epicardial explant. Filled arrowhead shows invading EYFP-Myc epicardial cells.
We found that in \textit{iMOS}^{\text{T1-Myc}} mosaics, even though the majority of the IVS cardiomyocytes overexpress Myc, there is no colonization of the LV; indicating Myc overexpression is unable to induce cardiomyocytes colonization of remote regions (figure 32 A, B).

\textit{Wt1-Cre} has also been shown to recombine cells from the endocardial/endothelial lineage, as well as hematopoietic progenitors (Alberta et al., 2003).

To study whether either of these cell types could be transdifferentiating upon Myc overexpression and giving rise to cardiomyocytes, we took advantage of the \textit{Tie2-Cre} mouse line that recombines both endocardial/endothelial lineage and hematopoietic progenitors. \textit{iMOS}^{\text{T1-Myc}} activation in blood and endothelium didn’t show any contribution to cardiomyocytes in the E14.5 embryonic heart (figure 32 C, C’), indicating that Myc overexpression in the \textit{Tie2-Cre} lineage is unable to induce transdifferentiation to cardiomyocytes.
**Ex-vivo epicardial assays do not show a differentiation of the epicardium to cardiomyocytes**

We then decided to address if Myc overexpression was able drive the epicardial cells towards the cardiomyocyte lineage in an epicardial explant culture system.

We performed explant assays from \textit{iMOS}^{WT} and \textit{iMOS}^{T1-Myc} mosaics at E10.5. After 6 days of culture, \textit{iMOS}^{WT} and \textit{iMOS}^{T1-Myc} explants showed an epicardial layer of cells typically cobble-stone shaped with some differentiation to mesenchymal cells mostly at the edges of the culture (figure 33 A-B’).

However, we were unable to detect cardiomyocytes by c-TnT staining or beating after scoring around 30,000 cells from different explants. Moreover, in the previously mentioned co-explant assays, invading epicardial cells from \textit{iMOS}^{T1-Myc} didn’t show myocardial differentiation (figure 29 C,C’).

It has been reported that proepicardial explants (Garriock et al., 2014) spontaneously give rise to cardiomyocytes, so we decided to assess if Myc overexpression could promote cardiomyocyte differentiation from proepicardium.

We performed proepicardial explants from E9.0 hearts of \textit{iMOS}^{WT} and \textit{iMOS}^{T1-Myc} and after 24 hours beating cells could be scored. We detected contribution to beating cells from \textit{Wt1-Cre} lineage in \textit{iMOS}^{WT} explants but we couldn’t detect any increase in the contribution to cardiomyocytes upon Myc overexpression.

These results show that assays do not support a role of Myc in driving the cardiomyocyte fate from epicardial cells.

![Ex-vivo epicardial assays](image)

**Figure 33. Proepicardium explants give rise to cardiomyocytes spontaneously as opposed to epicardial explants regardless of Myc expression**

\textbf{A-B’} Proepicardial explants performed at E10.5 after 6 days in culture from \textit{iMOS}^{WT} (WT) (A) and \textit{iMOS}^{T1-Myc} (MYC) (B). Bar 200\mu m A’ and B’ show magnification of cultures shown in A and B where cells display a typical “cobblestone” morphology. Bar 100\mu m.  

\textbf{C-D’} Proepicardial explants cultured for 48h from \textit{iMOS}^{WT} (WT) (C) and \textit{iMOS}^{T1-Myc} (MYC) (D) where big clusters of beating cells were detected to be positive for cardiac Tnt staining. Bar 200\mu m. C’ and D’ show a magnified area from C and D where EYFP+ cardiomyocytes are detected. Bar 50\mu m.
Contribution of Wt1 lineage to cardiomyocytes upon Myc overexpression takes place before establishment of the epicardial layer

To pin down the origin of cardiomyocytes from Wt1-Cre lineage, we decided to explore the origin of Wt1-Cre lineage derived cardiomyocytes in earlier developmental stages.

We analysed the contribution to cardiomyocytes in stages ranging from E9 to E9.5. Surprisingly, we found a small contribution to cardiomyocytes in both iMOSWT and iMOSWT-Myc at a similar proportion (around 75% of the embryos); at various locations of the embryonic hearts, with no reproducible pattern (figure 34 A-D).

These observations suggest that the contribution of the Wt1-Cre lineage to cardiom-earily labeled cardiomyocytes that would then expand by cardiomyocyte cell competition.

We then decided to directly test the contribution of the epicardial layer to the cardiomyocyte population at later stages, which would avoid the confounding effect of the early contribution of the Wt1-Cre lineage. For this, we used again a Wt1 driver but this time controlling a tamoxifen-inducible Cre.

We induced recombination injecting between E9-E9.5 and we found that even with the highest tolerable tamoxifen dose, although we detected recombination in the epicardium at E14.5, we were unable to detect any recombined cardiomyocyte (figure 34 E-F).

Taken together, these results indicate that in most likelihood, Myc overexpression in the epicardial layer does not drive epicardium or EPDC differentiation towards the cardiomyo-
Most likely, it is the contribution of the Wt1-Cre lineage to the early cardiomyocyte lineage what explains the presence of cardiomyocytes in these experiments.

These cardiomyocytes would then expand by cell competition colonizing large portions of the ventricles. Whether this early contribution of the Wt1-Cre lineage reflects an early expression of endogenous Wt1 in the cardiomyocyte lineage or a failure of the Cre line to recapitulate Wt1 expression at early developmental stages remains to be determined.
DISCUSSION

Something good will come of all things yet
(Jack Kerouac)
In this thesis we have demonstrated the ability of Myc mild overexpression in a mosaic fashion to trigger a response in the heart that eliminates cells with relative lower Myc levels, preserving organ size and function.

Previous studies have pointed to Myc as an inducer of pathological responses in the heart, both during development, when it triggers cardiomyocyte overproliferation and heart hyperplasia (Jackson et al., 1990); and in an adult context, where Myc overexpression induces cell hypertrophy which eventually leads to cardiac failure and death (Xiao et al., 2001).

These studies, however, rely on strong cardiac promoters to drive Myc homogeneous overexpression and thus, cannot be used as a reference for milder Myc overexpressions; such as the one used in this thesis.

Myc overexpression through the iMOS system in the heart is mild and has not rendered any pathological effects neither during development; nor in adulthood, at anatomical or functional level. This goes in agreement to what has been previously described for Myc levels through the Rosa 26 promoter; which do not induce cardiac hypertrophy even with two extra Myc alleles.

Upon Myc overexpression in adult hearts we have detected, through differential expression analysis, a pattern that resembles cardiac overload response. The activated pathways (Nppa, HGF), are a consequence of reactivation of fetal programs. This reactivation has been described upon higher demands in cardiac function and is cardioprotective and benign (Kishimoto et al., 2001, Kuhn et al., 2002, Madonna et al., 2012).

HGF in particular has been described not only to play a protective role but also to be implicated in heart regeneration (Madonna et al., 2012). Moreover, a specific hypertrophy-upregulated pathway (EGF), usually present in maladaptive hypertrophic responses (Lee et al., 2011) was downregulated in our experimental context. At the light of the transcriptomic analysis and the lack of pathological effect, neither anatomical nor functional, it is clear that Myc levels used to study cell competition in the heart are within homeostatic values, and do not induce any functional impairment or defect in the developing or adult heart.

Myc overexpression in the developing heart is able to induce cell competition, eliminating those cardiomyocytes with relative lower Myc levels, and it promotes these changes in cell composition without exerting alterations in the function or size of the heart.

The fact that cardiomyocytes are eliminated during heart development goes in agreement with previous studies which have highlighted its enormous plasticity, (Drenckhahn et al., 2008) being able to compensate for defective cell loss during morphogenesis whilst preserving organ size and function and give rise to a phenotypically normal heart. Our results indicate that even WT cells can be eliminated by cell competition when confronted with more active cells. This suggests that the replacement ability observed by Drenckhahn et al. could be boosted by cell competition, although this aspect was not explored in this model.

Moreover, we have shown that this plasticity is different if we induce cell competition in the second heart field population of the heart, suggesting that inducing cell competition at different differentiation stages (in this case, prior to the addition of precursors to the heart tube) (Cai et al., 2003) could have an effect on the replacement of WT cardiomyocytes; although it could also be the case that second heart field progenitors are highly sensitive to heterogeneity in Myc levels per se and thus...
the competitive response is exacerbated. In the light of these data, and because we had detected Myc endogenous expression also in second heart field precursors, endogenous cell competition could also be taking place in this particular population.

However, rescuing this cell population from death by mosaic p35 overexpression did not result in a cell population with lower Myc levels, suggesting that programmed endogenous cell competition does not take place during cardiac development.

The results obtained with the induced cell competition however show that cardiomyocytes remain sensitive to fitness heterogeneity and do activate cell competition in response to it. These observations suggest cell competition could be used contingently to eliminate accidentally defective cardiomyocytes.

Whereas the mechanisms underlying cell competition remain elusive (not only in mammals but also in Drosophila), a common feature is the elimination of “loser” cells by apoptosis (Claveria et al., 2013). This also holds true in heart development induced cell competition, where it has also been shown to rely on short-range signals to be induced; in a similar fashion to what has been described both in mammals (Claveria et al., 2013) and in Drosophila (Moreno and Basler, 2004, Moreno et al., 2002).

We have not detected, however, a compensatory overproliferation of winner cells or an increase in their size as a compensatory mechanism to ensure organ size, as it had been reported in Drosophila in postmitotic tissues (Tamori and Deng, 2013).

Moreover, these results agree with previously reported effect of Myc overexpression through Rosa 26 promoter in the heart (Murphy et al., 2008) and the described cell competition in the mammalian epiblast (Claveria et al., 2013). Maintenance of cell numbers and organ size could be due to the fact that cell competition is a rather local phenomenon; since apoptosis is scarce during heart development (Poelmann et al., 2000) and probably because a subtle increase in the proliferation rate of both populations compensates for the loss of wild-type cells; thus preserving organ size and cell number but not being detected through our experimental approach.

Further attempts to gain insight in cell competition mechanisms have been negative; Flower elimination did not show any alteration of the Myc-induced competition in the heart, suggesting alternative mechanisms for sensing cellular fitness in mammalian cardiomyocytes must be present.

We have tested competition by confronting cell populations with different doses of overexpressed Myc and endogenous Mycn. Mycn has been previously shown to functionally replace Myc (Malynn et al., 2000) and by depleting Mycn we have shown that competition and its intensity depend on the comparison of relative Myc functional doses between neighbouring cardiomyocytes, rather the absolute Myc levels.

Moreover, we have shown that Myc-expressing cardiomyocytes are able to promote a very strong elimination of Mycn KO cardiomyocytes from the developing heart, rescuing the otherwise embryonic lethal phenotype of Mycn mutants (Harmelink et al., 2013).

Elimination of Mycn KO cardiomyocytes, however, is not due to a cell autonomous deleterious effect of the mutation since it has been shown that Mycn deficiency doesn’t increase apoptotic rates in cardiomyocytes during development (Harmelink et al., 2013).

Therefore, the strong depletion in Mycn KO cells is attributable to an active elimination by cell competition. These results indicate that cell competition underlies the plastic capacity of the developing heart to eliminate flawed
cells and restore myocardial function. Interestingly, this ability is maintained in adult life, albeit at a lower rate. Despite cardiomyocytes being mostly a postmitotic cell population, cell competition appears to be able to displace the WT population without altering cardiac function. In contrast, in an example of postmitotic cell competition in Drosophila, lost cells are replaced by hypertrophy of the winners (Tyler et al., 2007).

In adult heart competition there are, however, notable differences with that observed in the developmental context. Wild-type cardiomyocytes are eliminated by a mechanism prevented by p35 expression, and even though apoptosis wasn’t directly detected, a role for autophagy-driven cell death was found.

Autophagy is a catabolic process by lysosomal degradation of cytoplasmic content. Homeostatic autophagy is usually protective and needed to maintain healthy cardiomyocytes, but exacerbated autophagy levels can be deleterious and lead to cell death. In several studies it is autophagy and not apoptosis what leads to cell death in cardiomyocytes (Zhu et al., 2007, Knaapen et al., 2001).

Apoptosis and autophagy pathways have been shown to be tightly linked and their crosstalk has been largely reported (Reviewed in Rubinstein and Kimchi, 2012) and (Jain et al., 2013). Moreover, a master regulator of deleterious autophagy, Beclin1, is inhibited by Bcl2-family of antiapoptotic proteins (Pattingre et al., 2005).

The activation of autophagy in loser cells upon cell competition in the adult heart is most likely related to the specific characteristics of adult cardiomyocytes. Since their size is several times bigger than that of macrophages, in order for corpses to be cleared, presumably they need to be downsized, which would be achieved by increasing their autophagy levels. It has been described that autophagy can facilitate events leading to cell death (Qu et al., 2007) and the classic elimination of giant cells of the salivary gland in Drosophila involves caspase-dependent autophagic cell death (Martin and Baehrecke, 2004).

Interestingly, the observed replacement of cardiomyocytes in the adult context is relevant to a long-debated question as to whether the heart is able to turn-over its cardiomyocyte population and the putative source of new cardiomyocytes. Since there’s an increase in the relative EYFP-Myc cell population and due to experimental design it seems likely that the new cardiomyocytes generate from pre-existing ones. Some authors argue that Myh6 is expressed in certain postnatal cardiac stem cells (Kwon et al., 2007, Bailey et al., 2009), which could be a confounding factor as of the source of the newly formed

![Figure 35. Schematic model on the results obtained in this thesis in cell competition in the developing and adult heart](image)

During development, Myc overexpressing cardiomyocytes expand at the expense of WT, which are eliminated by apoptosis. In the adult heart, Myc overexpressing cardiomyocytes expand and autophagy is induced in WT cardiomyocytes prior to their elimination.
cardiomyocytes. Other studies, however, state the contrary (Ali et al., 2014); so even though this remains a controversial issue, it is highly likely that newly formed EYFP Myc cardiomyocytes arise from pre-existing ones; which would also be in agreement with previous reports on cardiomyocyte turnover (Ali et al., 2014, Senyo et al., 2013, Bergmann et al., 2009, Bersell et al., 2009).

Moreover, there is an increase in the BrDU incorporation in EYFP Myc cardiomyocytes that would support this hypothesis, accounting for the relative increase in this population. (Assuming of course that DNA synthesis results in cytokinesis). In fact, the ratio between mono and multinucleated cardiomyocytes was maintained, suggesting that increased bi-nucleation events were balanced with proliferation of mononucleated cardiomyocytes (Bersell et al., 2009).

This proliferation cannot be attributed to a cell-autonomous effect, since homogeneous overexpression of up to two copies of Rosa26-MycER do not lead to cardiomyocyte overproliferation (Murphy et al., 2008), and thus, most likely, corresponds to a mechanism that compensates for the loss of WT cells.

The compensatory nature of this proliferation is supported by the observation that in iMOS\textsuperscript{1-MycT2: p35} mosaics, heart size and shape is maintained. Therefore, our results suggest that local cell competition and compensatory proliferation balance each other preserving heart size.

Results from differential expression analysis showed activation of fetal programs that are typical hallmarks of cardiac overload and hypertrophy. This activation did not lead to phenotypic or functional cardiac alterations, suggesting they are directly activated by Myc in the absence of any cardiac stress.

Disruption of these pathways has been shown to lead to cardiac pathologies and death (Oliver et al., 1997, Kuhn et al., 2002) and they have been shown to be protective in induced hypertrophy models (Kishimoto et al., 2001).

Overall, these changes can be attributable to an autonomous effect of Myc overexpression and further transcriptomic and proteomic assays must be performed in detail in both winner and loser populations to shed light in mechanisms regulating cell competition.

However, it is still to be explored whether Myc mild activation in cardiomyocytes triggers by itself a protective response in hypertrophic or ischemic models.

**Epicardium**

Given the limited regenerative capacity of the mammalian adult heart, the search for cells that can stimulate cardiac repair is intense, and the epicardium has arisen as a potential source of cardiac progenitors (Wessels and Perez-Pomares, 2004).

The understanding of the full potential of epicardial cells to constitute a source of progenitors with regenerative ability is of key importance. Therefore, the quest to understand the full potential of this population during development has been a focal point in cardiac developmental and regenerative studies.

In this thesis we obtained results apparently pointing to Myc’s ability to induce differentiation of epicardial or epicardial-derived cells to the cardiomyocyte lineage. Initial results showed a very strong contribution to the cardiomyocyte lineage, which would be in agreement with previous reports on the potential of epicardial cells to contribute to the developing myocardium (Zhou et al., 2008, Cai et al., 2008).

However, studies of epicardial fate are confusing because of unreliability of the tools used in the fate-mapping experiments (Rudat and Kispert, 2012, Zhou et al., 2008, Zhou and Pu, 2012).
Genetic fate mapping studies strongly rely on Cre expression in the precursor tissue without any leakiness in the target tissue. Regarding *Tbx18-Cre*, for example, contribution of EPDCs to myocardium has been debated (Christoffels et al., 2009) and direct Tbx18 expression in cardiomyocytes has been reported (Zeng et al., 2011). It has been shown that *Wt1-Cre* lines are not completely reliable recapitulating Wt1 expression and suggested not to be useful to assign an epicardial origin of the traced cells (Rudat and Kispert, 2012).

Moreover, use of the inducible *Wt1-CreERT2* line yields a very inefficient recombination and studies on its contribution to the cardiomyocyte pool are also contradictory (Zhou and Pu, 2012, Rudat and Kispert, 2012, Zhou et al., 2008). Despite all of these data regarding the reliability of the tools used; the specific Cre line used for this study has not been reported to label cardiomyocytes (Wessels et al., 2012, Wilm et al., 2005) besides those found sparsely in the IVS. The reason for a putative sporadic Cre activation in cardiomyocytes in this line (*Wt1-CreEGFP*) (Wessels et al., 2012) remains unknown but has also been reported elsewhere (Zhou and Pu, 2012).

Some studies discard the expression of Wt1 in cardiomyocytes during development (Zeng et al., 2011); but only addressed developmental stages from E10.5 onwards. However, expression of Wt1 in cardiomyocytes has been detected at stage E9.5, albeit weak (Rudat and Kispert, 2012), and could underlie our observation.

All of these studies highlight that results obtained using these tools need to be carefully assessed.

In our experiments, despite the initial appearance, we could not relate the contribution of the *Wt1-Cre* lineage to cardiomyocytes to an epicardial origin. Our fate-mapping performed at E14.5 showed a strong contribution to cardiomyocytes upon Myc overexpression, but we have been unable to induce that differentiation in vitro and this observation has not been reproduced inducing temporal conditional epicardial lineage tracing.

Moreover, we have detected the presence of cardiomyocytes from a *Wt1-Cre* lineage prior to the appearance of the epicardium. This contribution was poorly reproducible and not dependent on Myc activation since it was observed equally in *iMOSWT* and *iMOST1-Myc* mosaics.

The fact that Myc overexpression provokes very efficient and fast competition in early heart precursors and cardiomyocytes and the undetectable differences between Myc and control mosaics as we have detected in Islet1 progenitors, suggests that this contribution of the *Wt1-Cre* lineage to cardiomyocytes is produced from de novo activation in cardiomyocytes shortly before the time of observation (E9-9.5) and does not result from an early recombination in earlier cardiac precursors.

The question on the origin and nature of the cardiomyocytes present at E14.5 and P0 upon Myc overexpression is therefore still unanswered, although it seems that early expression in cardiomyocytes at E9.5 and further expansion of these cardiomyocytes by cell competition is the most likely scenario.

The inability to detect this cardiomyocyte population in the free walls of the ventricles at late stages in the WT mosaics is intriguing.

One possibility is that this early *Wt1-Cre*-labeled cardiomyocytes represents a subset of cardiomyocytes with limited ability to contribute to the definitive myocardium except in the IVS, and upon Myc overexpression are rescued and promoted to contribute to the ventricular free wall through cell competition.

Further studies need to be performed to address this hypothesis and if this is the...
case, on the implications of rescuing this subset of cardiomyocytes for development and homeostasis.
CONCLUSIONS

The beauty of things must be that they end
(Jack Kerouac)
Conclusions

1.- Myc mild overexpression in a mosaic fashion induces cell competition in the developing heart, eliminating cells with lower Myc levels.

2.- Elimination of WT cardiomyocytes is a phenotypically silent process and heart morphology and function are preserved.

3.- Elimination of WT cardiomyocytes relies on short range interactions.

4.- Second heart field progenitors show a strong response to cell competition.

5.- Adult cardiomyocytes compete, eliminating those with relative lower Myc levels in homeostasis.

6.- Cell competition in the adult heart relies on proliferation of “winner cardiomyocytes” at the expense of those with relative lower Myc levels, which activate autophagic pathways prior to their elimination.

7.- Myc mosaic overexpression at moderate levels in the adult heart induces activation of fetal programs typical of a protective response to cardiac overload.

8.- Myc mosaic overexpression in Wt1 lineage induces cell competition in epicardium and epicardial derived lineages.

9.- Wt1-Myc overexpression promotes the contribution of Wt1 lineage to cardiomyocytes in the ventricular free walls, although epicardial contribution to this lineage is discarded.
Conclusiones

1.- La sobreexpresión moderada de Myc en mosaico induce competición celular en el corazón durante la gestación, eliminando aquéllas células con menor nivel relativo de Myc.

2.- La eliminación de los cardiomiocitos salvajes es un proceso fenotípicamente silencioso y la morfología y función del corazón están inalteradas.

3.- La eliminación de los cardiomiocitos salvajes depende de interacciones a corta distancia.

4.- Los progenitores del campo cardíaco secundario tienen una respuesta más acusada a la competición celular.

5.- Los cardiomiocitos adultos también son sensibles a la competición celular inducida, eliminándose aquéllos con menos nivel de Myc.

6.- La competición celular en el corazón adulto depende de la proliferación de los cardiomiocitos “ganadores” a expensas de aquellos con menor nivel relativo de Myc, que activan vías de señalización de autofagia previamente a ser eliminados.

7.- La sobreexpresión moderada de Myc en el corazón adulto induce la activación de programas de expresión fetales característicos de una respuesta cardioprotectora en respuesta a la sobrecarga cardíaca.

8.- La sobreexpresión de Myc en mosaico en progenitores Wt1 positivos induce competición en el epicardio y linajes derivados.

9.- La sobreexpresión de Myc en mosaico en progenitores Wt1 positivos promueve su contribución a cardiomiocitos de la pared libre del ventrículo, aunque se descarta la contribución directa del epicardio.
BIBLIOGRAPHY

The saddest aspect of life right now is that science gathers knowledge faster than society gathers wisdom
(Isaac Asimov)


BALLESTEROS-ARIAS, L., SAAVEDRA, V. & MORATA, G. Cell competition may function either as tumour-suppressing or as tumour-stimulating factor in Drosophila. Oncogene.


CAI, C. L., LIANG, X., SHI, Y., CHU, P. H., PFAFF, S. L., CHEN, J. & EVANS, S. 2003. Isl1 identifies a cardiac progenitor population that proliferates prior to differ-
rentiation and contributes a majority of cells to the heart. Dev Cell, 5, 877-89.


MURPHY, D. J., JUNTTILA, M. R., POUYET, L., KARNEZIS, A., SHCHORS, K., BUI, D. A., BROWN-SWIGART, L.,


W


X


Y


Z


ZHOU, B., MA, Q., RAJAGOPAL, S., WU, S. M., DOMIAN, I., RIVERA-FELICIANO, J., JIANG, D., VON GISE, A., IKEDA, S.,


ACKNOWLEDGEMENTS

What separates privilege from entitlement is gratitude
(Brené Brown)
ACKNOWLEDGEMENTS
Cell Reports

Cell Competition Promotes Phenotypically Silent Cardiomyocyte Replacement in the Mammalian Heart

Graphical Abstract

Highlights
Cardiomyocytes are sensitive to Myc-induced competition in development and adult life
Cardiomyocyte competition is driven by short-range interactions leading to cell death
Cardiomyocyte replacement by cell competition is phenotypically silent

Authors
Cristina Villa del Campo, Cristina Clavería, Rocio Sierra, Miguel Torres

Correspondence
mtorres@cnic.es

In Brief
Cardiomyocytes of the mammalian heart are generated during prenatal and early postnatal development and show very low turnover during adult life. Strategies for cardiomyocyte generation and replacement are therefore essential for repairing the diseased heart. Villa del Campo et al. show that mosaic Myc overexpression in cardiomyocytes leads to the phenotypically silent replacement of normal cardiomyocytes by the Myc-overexpressing ones, through a process known as cell competition. This work uncovers a mechanism potentially relevant to cardiac repair.

Accession Numbers
GSE58858
Cell Competition Promotes Phenotypically Silent Cardiomyocyte Replacement in the Mammalian Heart

Cristina Villa del Campo,1 Cristina Clavería,1 Rocio Sierra,1 and Miguel Torres1,2
1Departamento de Desarrollo y Reparación Cardiovascular, Centro Nacional de Investigaciones Cardiovasculares (CNIC), c/ Melchor Fernández Almagro, 3, E-28029 Madrid, Spain
*Correspondence: mtorres@cnic.es
http://dx.doi.org/10.1016/j.celrep.2014.08.005
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

SUMMARY

Heterogeneous anabolic capacity in cell populations can trigger a phenomenon known as cell competition, through which less active cells are eliminated. Cell competition has been induced experimentally in stem/precursor cell populations in insects and mammals and takes place endogenously in early mouse embryonic cells. Here, we show that cell competition can be efficiently induced in mouse cardiomyocytes by mosaic overexpression of Myc during both gestation and adult life. The expansion of the Myc-overexpressing cardiomyocyte population is driven by the elimination of wild-type cardiomyocytes. Importantly, this cardiomyocyte replacement is phenotypically silent and does not affect heart anatomy or function. These results show that the capacity for cell competition in mammals is not restricted to stem cell populations and suggest that stimulated cell competition has potential as a cardiomyocyte-replacement strategy.

INTRODUCTION

Cell competition is a mechanism that eliminates suboptimal cells from tissues when “fitter” cells are present (reviewed in Baker, 2011; de Beco et al., 2012; Levayer and Moreno, 2013; Vincent et al., 2013). Cell-to-cell heterogeneity in anabolic capacity led to the first description of cell competition, during Drosophila development (Morata and Ripoll, 1975), and is currently the most frequent feature found associated with this phenomenon. The fluctuations in anabolic capacity that trigger cell competition are within a physiological range, and “loser” cells are viable and capable, in the absence of fitter cells, of sustaining tissue growth and performance. Cell competition can thus be envisioned as an optimization mechanism enabling tissues to achieve their best possible cellular composition by favoring the fitter cell population at the expense of less-fit cells. Cell competition can be experimentally induced by generating loser cells through the mosaic reduction of cell anabolism (Morata and Ripoll, 1975) or by generating “winner” cells through the mosaic increase of cell anabolism (supercompetition) (de la Cova et al., 2004; Moreno and Basler, 2004). The conserved cell anabolism regulator Myc is involved in cell growth and proliferation (reviewed in Dang, 2013; Gallant, 2013; Levens, 2013) and plays essential roles in mammalian development (Davis et al., 1993; reviewed in Hurlin, 2013). Moderate increase in Myc levels in a mosaic fashion in Drosophila imaginal discs (de la Cova et al., 2004; Moreno and Basler, 2004) and pregastrulation mammalian embryos (Clavería et al., 2013) induces supercompetition, leading to the phenotypically silent replacement of wild-type cells by Myc-overexpressing cells without overt phenotypic consequences. In addition, natural Myc fluctuations trigger cell competition in the mouse epiblast (Clavería et al., 2013), indicating an endogenous role for cell competition in optimization of the pool of precursor cells that generate the embryo. Mosaic Myc overexpression also induces cell supercompetition in embryonic stem cell cultures (Clavería et al., 2013; Sancho et al., 2013), and hematopoietic stem cells have been shown to undergo p53-dependent cell competition (Bondar and Medzhitov, 2010; Marusyk et al., 2010). These observations suggest that the capacity for cell competition might be associated with stemness, but this hypothesis has not been tested. Here, we explored this issue by asking whether cell competition could be induced in one of the first lineages to differentiate in the mammalian embryo, the cardiac lineage.

Cardiac precursors originate early in gastrulation within the anteriormost embryonic mesoderm (reviewed in Vincent and Buckingham, 2010). During mouse gastrulation, cardiac precursors migrate anteriorly and form a cardiac crescent, which by embryonic day 8.0 (E8.0) has folded into a primary tube containing still-proliferative but differentiated and functionally active cardiomyocytes (reviewed in Evans et al., 2010; Rana et al., 2013). A subset of cardiac precursors remain undifferentiated in the second heart field (Kelly et al., 2001) and are progressively added to the heart tube until cardiac chambers and outflow and inflow tracts are definitively laid down around E10. After birth, most cardiomyocytes stop dividing and undergo hypertrophy to establish the mature definitive myocardium (Soonpaa et al., 1996). Here, we show that mosaic Myc overexpression in cardiomyocytes at levels that do not alter heart anatomy or function promote the phenotypically silent replacement of wild-type (WT) cardiomyocytes in the mouse fetal and adult myocardium through cell competition. Our results show the widespread ability of mammalian cells to undergo Myc-driven cell competition and identify cell competition as an efficient mechanism for phenotypically silent substitution of cell populations while preserving organ function.
RESULTS

Mosaic Myc Overexpression Induces Cardiomyocyte Population Expansion in the Developing Heart

To test the consequences of overexpressing Myc in the developing heart, we used the recently established iMOS system (Claveria et al., 2013), which allows the Cre-mediated conditional induction of random genetic mosaics. We first generated control random genetic mosaics in cardiac lineages using Nkx2.5-Cre (Stanley et al., 2002) to induce the iMOSWT transgene, which produces a random mosaic of enhanced yellow fluorescent protein (EYFP) and enhanced cyan fluorescent protein (ECFP) WT cells. Quantitative confocal analysis of iMOSWT recombination at E10.5 in iMOSWT; Nkx2.5-Cre hearts confirmed the mosaic expression pattern of the two reporter proteins in embryonic cardiomyocytes at a reproducible cell population ratio, as previously described (EYFP:ECFP = 3:1) (Figures 1A–1C). The fluorescence protein distribution pattern indicated iMOS activation throughout the embryonic heart (Figures 1A–1C). We then generated Nkx2.5-Cre-induced iMOSWT-Myc mosaics, in which the EYFP cell population moderately overexpresses Myc (Claveria et al., 2013) (Figures 1D–1F). Confocal analysis of EYFP simultaneously with Myc protein immunodetection showed the expected increase in MYC levels in the EYFP cell population of iMOSWT-Myc mosaics, but not iMOSWT mosaics (Figures 1I and 1J). We then quantified the contribution of the mosaic cell populations by confocal analysis at different stages of heart development. In the iMOSWT-Myc mosaics we found a progressive reduction in the relative abundance of the ECFP-WT cell population—and a concomitantly increased relative abundance of the EYFP-Myc population—that was not observed in the iMOSWT mosaics (Figures 2A–2G). The proportion of ECFP cardiomyocytes at E9.5 in iMOSWT-Myc mosaics was lower (but not significantly) than that observed in iMOSWT mosaics. From then on, the relative abundance of the ECFP-WT population in iMOSWT-Myc mosaics showed a progressive decline to 60% of the iMOSWT value at E10.5, 40% at E11.5, and 25% at postnatal day 0 (P0) (Figure 2G). The shift in cell populations thus takes place mostly in a narrow time window between E9.5 and E11.5.

Previous studies showed that Myc overexpression in cardiomyocytes during fetal life can lead to pathological cardiac hyperplasia (Jackson et al., 1990). However, in these studies, Myc expression was 20-fold above normal. To determine whether the overexpression levels used here could lead to cardiac hyperplasia we characterized adult heart anatomy and cardiomyocyte size. P0 hearts from Nkx2.5-Cre-recombined iMOSWT-Myc and iMOSWT mice were of normal size and anatomy (Figures S1A and S1B and data not shown), and cardiomyocytes from the iMOSWT-Myc hearts were of a similar size to those from iMOSWT hearts (Figure S1C).

The shift in the cell population proportion observed in iMOSWT mosaics thus results from expansion of the EYFP Myc-overexpressing cardiomyocyte population and a concomitant reduction of the ECFP WT population relative contribution, without disruption of heart cell composition or anatomy. These results also indicate that the levels of Myc overexpression from the iMOSWT-Myc allele are within the limits that allow normal cardiomyocyte development and do not provoke hyperplasia.
Islet-1 Progenitors Are Highly Sensitive to Myc-Induced Cell Competition

We next explored the impact of inducing Myc mosaicism in Islet1+ cardiac progenitors. For this, we generated iMOS$^{T1}$-Myc mosaics in second heart field (SHF) progenitors using Islet1-Cre (Yang et al., 2006). This Cre driver provides partial interspersed recombination of the SHF cell population, resulting in about 7% EYFP recombined cardiomyocytes in the right ventricle (RV) of iMOS$^{WT}$ mosaics (Figures 3A, 3D, 3E, and 3F). In contrast, the RV of iMOS$^{T1}$-Myc; Islet1-Cre hearts on average contained 40% EYFP cardiomyocytes at P0, representing a 5.7-fold expansion during gestation of the original EYFP cardiomyocyte population (Figures 3B, 3D, 3F, and 3F). In addition, the ECFP cardiomyocyte population in the Islet-Cre-induced iMOS$^{T1}$-Myc mosaic hearts was almost completely eliminated by P0 (Figures 3E, 3F, and 3H). These results indicate a more active elimination of the mosaic ECFP-WT cell population and a continued expansion of the Myc-overexpressing cardiomyocyte population during fetal life, in a context in which it is continuously confronted with WT cardiomyocytes. We then characterized the temporal progression of ECFP cardiomyocyte depletion in iMOS$^{T1}$-Myc mosaics, finding that this population was already reduced to 40% of its original contribution by E9.5, with further progressive reduction until the final residual presence at birth (Figures 3I–3L). The enhanced early elimination of WT progenitors in the Islet-Cre-induced mosaics indicates that undifferentiated Islet1+ cardiac progenitors are highly sensitive to Myc mosaicism.

The Myc-Overexpressing Cardiomyocyte Population Expands by Apoptosis-Driven Cell Competition

To study the mechanisms underlying the expansion of the Myc-overexpressing cardiomyocyte population during development, we first determined the abundance of PHH3$^+$ cells and bromodeoxyuridine (BrdU) incorporation in iMOS mosaics at E10.5, when the shift in the cell population proportion is taking place. Overall, PHH3$^+$ and BrdU$^+$ cell frequencies did not differ significantly between iMOS$^{T1}$-Myc and iMOS$^{WT}$ cardiomyocytes (Figure S2). Moreover, the PHH3$^+$ and BrdU$^+$ cell frequencies in the EYFP cell population of iMOS$^{T1}$-Myc mosaics was not different from that in the ECFP population (Figures S2D and S2E). These results fit with previous studies showing that the Myc dosage induced by a single Rosa26 allele does not increase proliferation rates in most tissues (Clavería et al., 2013; Murphy...
et al., 2008) and suggest that the shift in cardiomyocyte populations is not produced by overt differences in cell proliferation between the two cell populations.

To evaluate the role of cell death in the depletion of WT cardiomyocytes, we generated mosaics of the iMOS T1-Myc/T2p35 strain, which produces a random mosaic of EYFP-Myc and ECFP-p35 cells. p35 is a baculoviral caspase inhibitor able to prevent apoptosis in insects and mammals (Clavéria et al., 1998; Hay et al., 1994). Quantitative confocal analysis of P0 hearts from iMOS T1-Myc/T2p35 mosaics induced with either Nkx2.5-Cre or Islet1-Cre showed that the p35-expressing ECFP population was substantially, although not completely, protected against elimination (Figures 2H–2N, 3C, and 3G–3H). This result indicates that cell death is a predominant mechanism in the population shift observed in iMOS T1-Myc mosaics.

However, expansion of the EYFP-Myc cell population did not significantly affect Islet1-Cre-induced iMOS T1-Myc/T2p35 and iMOS T1-Myc mosaics (Figure 3D), indicating that expansion of Myc-enriched cardiomyocytes can progress through elimination of nonrecombined WT cardiomyocytes even when small numbers of apoptosis-resistant ECFP-p35 cardiomyocytes are present.

We next scored apoptosis by TUNEL at E10.5 in the Nkx2.5-Cre-induced mosaics, concentrating on the outflow tract (OFT) because this region had higher rates of apoptosis in the iMOS WT mosaics. The iMOS T1-Myc mosaics had a 5-fold higher overall apoptosis rate than iMOS WT mosaics (Figures 4A–4C). Furthermore, the apoptosis rate in ECFP-WT cells of the iMOS T1-Myc mosaics was markedly higher than in the EYFP-Myc cells (Figures 4D–4F). Interestingly, the apoptosis rate varied between heart regions: whereas the ECFP/EYFP TUNEL ratio was 4- to 5-fold above baseline in the ventricles, in the OFT it was over 10-fold higher, indicating that ECFP-WT cardiomyocytes in this region are especially sensitive to mosaic Myc overexpression.

To study the range limit of the cellular interaction leading to ECFP-WT cardiomyocyte apoptosis in iMOS T1-Myc mosaics, we took advantage of the Islet-Cre strain. The low-rate, interspersed recombination induced by this line allowed us to score apoptosis separately for WT cardiomyocytes in direct contact...
with EYFP cells and those not in contact (Figures 4G–4H†). Apoptosis was 17-fold more frequent in WT cardiomyocytes in direct contact with Myc-overexpressing EYFP cardiomyocytes than in those not contacting EYFP cardiomyocytes (Figure 4I; Movie S1).

These results indicate that the expansion of Myc-overexpressing cardiomyocytes requires the elimination of neighboring WT cardiomyocytes through apoptosis triggered by direct cell-cell contact or short-range signaling. Our characterization thus establishes that the replacement of the WT cardiomyocyte population by the Myc-overexpressing population is due to apoptosis-driven cell competition.

**Myc Overexpression Induces Cardiomyocyte Population Expansion in the Adult Heart**

To determine whether increased Myc levels impact cardiomyocyte population homeostasis during adult life, we induced mosaicism in the adult cardiomyocyte population by using the tamoxifen-inducible aMHC-merCreMer strain (Sohal et al., 2001) (Figure 5A). Mosaics were induced by feeding animals tamoxifen during the first month after weaning, and hearts were analyzed immediately after tamoxifen cessation and at subsequent intervals up to 1 year (Figure 5A). This protocol produced an initial EYFP recombination slightly above 50% (Figure 6D). Previous studies have shown that strong Myc overexpression in cardiomyocytes of adult mice induces cardiomyocyte hypertrophy (Xiao et al., 2001). We thus first analyzed whether hypertrophy also resulted from long-term moderate Myc overexpression.

Tamoxifen-induced adult iMOS<sup>T1-Myc</sup> and iMOS<sup>WT</sup> mice showed no spontaneous cardiac malfunction and their hearts were of normal size and anatomy even after 2 months of an intense exercise protocol (Figures 5B–5E). Measurement of average cardiomyocyte 2D size, both in histological sections and in cultures of disaggregated cardiac cells (Figures 5F–5I), showed that cardiomyocytes in iMOS<sup>T1-Myc</sup> hearts were not only not bigger than those in iMOS<sup>WT</sup> hearts but also in fact slightly smaller (Figure 5J). Due to binucleation, adult cardiomyocytes could contain more than one EYFP-Myc copy, and the levels of EYFP are expected to correlate with the Myc dose in the iMOS<sup>T1-Myc</sup> mosaics. Analysis of per-cell cardiomyocyte size and EYFP level showed no
correlation between these two parameters in either iMOS\(^{WT}\) or iMOS\(^{T1-Myc}\) mosaic hearts (Figures 5K and 5L). These results show that sustained Myc overexpression from the iMOS\(^{T1-Myc}\) allele during adult life does not provoke cardiomyocyte hypertrophy. Heart size and heart/body weight ratios were moreover similar in both mosaics, indicating that overall cardiac cellular and organ anatomy are preserved.

We next determined the proportions of cardiomyocyte populations at different times after mosaic induction. While in iMOS\(^{WT}\) hearts the proportion of EYFP cardiomyocytes was 53% at 1 year of age (Figures 6A and 6D), in the iMOS\(^{T1-Myc}\) mosaics, the proportion increased progressively from a frequency similar to that found in iMOS\(^{WT}\) hearts to 66% at 1 year of age (Figures 6B and 6D). Interestingly, half of this enrichment took place during the first month of observation. Since there were no major changes in heart mass or cardiomyocyte size (Figures 5E and 5J), these observations suggest that Myc-overexpressing cardiomyocytes expand at the expense of WT cardiomyocytes during adult life. To directly test this, we determined the relative frequency of ECFP cardiomyocytes with respect to all fluorescent (ECFP+EYFP) cardiomyocytes in 1-year-old iMOS\(^{T1-Myc}\) and iMOS\(^{WT}\) mosaics (Figures 6E–6H). The ECFP cell frequency was ~60% lower in the iMOS\(^{T1-Myc}\) mosaics, confirming that the expansion of the Myc-overexpressing cardiomyocyte population is concomitant with a reduction in the WT population. Most adult cardiomyocytes in the mouse are tetraploid and contain two nuclei (Soonpaa et al., 1996); this, together with the partial recombination achieved by tamoxifen treatment, generates heterogeneous levels of EYFP-Myc content in cardiomyocytes, with a predicted predominance of cardiomyocytes with one or two active EYFP-Myc copies. We therefore refined our study to

**Figure 5. Mosaic MYC Overexpression in Adult Cardiomyocytes Is Phenotypically Silent**

(A) MHCmerCremer-recombined iMOS\(^{T1-Myc}\) mosaics and control littermates were treated as schematized for experiments in (B)–(L) and in Figure 6.

(B) Long axis M-mode echocardiography image from an iMOS\(^{T1-Myc}\) (MYC) mosaic WT littermate at t2.

(C) Graphs show ejection fraction (EF) and left ventricle (LV) mass from the echocardiographic study in the iMOS\(^{T1-Myc}\) mosaics (MYC) and in WT littermates (WT) at t3 (n \(\geq\) 3).

(D) EF and LV mass at t2 after a protocol of intense exercise from t0 to t2 (see Experimental Procedures).

(E) Heart/body weight ratios in the iMOS\(^{T1-Myc}\) mosaics (MYC) and in WT littermates (WT) at t3 (n \(\geq\) 3).

(F and G) Confocal sections showing wheat germ agglutinin (WGA) staining to highlight cell perimeters in iMOS\(^{WT}\) (WT) (F) and iMOS\(^{T1-Myc}\) (MYC) (G) mosaics at t3. Scale bar, 50 \(\mu\)m.

(H and I) Bright-field confocal section of cardiomyocytes isolated from iMOS\(^{WT}\) (WT) (H) and iMOS\(^{T1-Myc}\) (MYC) (I) mosaic hearts at t3. Scale bar, 50 \(\mu\)m.

(J) Size (2D area) of cardiomyocytes shown in (H) and (I). n \(\geq\) 4 hearts and 236 cells.*p < 0.1; **p < 0.05; ***p < 0.001. Horizontal bars represent mean values.

(K and L) EYFP fluorescence intensity plotted against cell size for cardiomyocytes isolated from iMOS\(^{WT}\) (WT) (K) and iMOS\(^{T1-Myc}\) (MYC) (L) mosaic hearts. Lines in (K) and (L) represent the regression line \((R^2 = 0.040 \times 10^{-11} + 0.007204, \text{ respectively})\).

Data in (C)–(E) are means ± SEM.

6B and 6D).
showed that the enrichment in EYFP fluorescence intensity was determined (\(\pm\)SEM. *p < 0.05 **p < 0.01 ***p < 0.001.

Figure 6. Myc Overexpression Induces Replacement of Adult Cardiomyocytes

A–C Confocal images of plated cardiomyocytes isolated at t3 (12 months after tamoxifen administration; see scheme in Figure 5) from \(\alpha\)MHCmerCremer-recombined \(\text{iMOS}^{WT}\) (WT) (A), \(\text{iMOS}^{T1-\text{MYC}}\) (MYC) (B), and \(\text{iMOS}^{T1-\text{MYC/T2-p35}}\) (MYC/P35) (C) mosaics, showing native EYFP expression and background autofluorescence. (D) Percentage of EYFP+ cardiomyocytes in cultures obtained from \(\alpha\)MHCmerCremer-recombined \(\text{iMOS}^{WT}\) (WT) hearts at t1 and t3 and from \(\text{iMOS}^{T1-\text{MYC}}\) (MYC) hearts at t1-t3 (n ≥ 3 and 300 cells). Data are means ± SEM.

(E–G) Confocal images of plated cardiomyocytes obtained as in (A)–(C), showing anti-GFP immunofluorescence, which identifies EYFP+ and ECFP+ cardiomyocytes. Scale bar, 50 μm.

(H) Quantification of data represented in (A)–(G) at t3. The graph on the left shows the absolute frequencies of EYFP-Myc and ECFP-WT cardiomyocytes in \(\text{iMOS}^{WT}\) (WT), \(\text{iMOS}^{T1-\text{MYC}}\) (MYC) and \(\text{iMOS}^{T1-\text{MYC/T2-p35}}\) (MYC/P35) mosaics. In the graph on the right, the same data were expressed as relative ECFP+/EYFP+ cardiomyocyte proportions relative to that observed in \(\text{iMOS}^{WT}\) (WT) mosaics, which was normalized to 100%.

(I) Graph represents the frequency of cardiomyocytes according to EYFP intensity in tamoxifen-induced \(\alpha\)MHCmerCremer-recombined \(\text{iMOS}^{WT}\) (WT) and \(\text{iMOS}^{T1-\text{MYC}}\) (MYC) mosaics, measured in cardiomyocytes isolated at t3, as in (A)–(C). The vertical dotted line marks the limit between background-fluorescent and EYFP-positive cardiomyocytes. Arrows indicate regions in which the frequencies overtly differ between the two mosaics studied. Data in bar graphs are means ± SEM.

Analysis of the Pathways Involved in Adult Cardiomyocyte Competition

To identify the pathways altered in the \(\text{iMOS}^{T1-\text{MYC}}\) adult mosaic heart, we performed a transcriptomic analysis by RNA sequencing (RNA-seq), comparing 8-week old \(\text{iMOS}^{T1-\text{MYC}}\) and control hearts (Figure S3). Among the genes more significantly up- or downregulated in \(\text{iMOS}^{T1-\text{MYC}}\) hearts, there is a strong representation of genes involved in the response to cardiac overload, in cell growth/division, in energy metabolism, and in apoptosis (Figure S3A). Gene set enrichment analysis on all genes present in the RNA-seq experiment again detected the protective response to cardiac overload in \(\text{iMOS}^{T1-\text{MYC}}\) hearts, including the activation of the atrial natriuretic peptide and fetal cardiomyocyte programs (Kishimoto et al., 2001; Kuhn et al., 2002) and the hepatocyte growth factor (HGF)/Rho/tissue remodeling pathways (Madonna et al., 2012). In contrast, the epidermal growth factor (EGF) pathway, involved in the development of pathological hypertrophy (Shah and Catt, 2003), was found repressed in \(\text{iMOS}^{T1-\text{MYC}}\) hearts. Regarding metabolic processes, activation of the ribosome biosynthesis, a typical response to Myc overexpression, was also detected. In parallel, activation of the lysosomal pathway was as well present, indicating that metabolic activity was globally increased including both anabolic and catabolic processes. With regard to the metabolic processes, \(\text{iMOS}^{T1-\text{MYC}}\) hearts showed a reduction in lipid catabolism and in assembly of the peroxisome, the main organelle for lipid catabolism, suggesting a modification in the fuel usage by Myc-overexpressing cardiomyocytes. A remarkable alteration was found in various regulators of the circadian rhythm; Dbp and Per1, 2, and 3 were upregulated and Amtl (Bmal1) was downregulated. Circadian rhythm transcription factors are essential regulators of cardiac metabolism and regulate the balance between lipid and glucose usage in the heart and display a feedback regulation with the oxidative phosphorylation pathway in the heart (Durgan and Young, 2010). A major regulator of cardiac metabolism, AMP-activated protein kinase, has also been described to undergo circadian regulation (Tsai et al., 2010), its regulatory subunit is overexpressed in the \(\text{iMOS}^{T1-\text{MYC}}\) hearts, and it can be activated by Myc overexpression (Nieminen et al., 2013). The results observed are therefore compatible with a modified metabolic status of the \(\text{iMOS}^{T1-\text{MYC}}\).
with either a direct or indirect impact of Myc overexpression on the circadian metabolic regulation. In agreement with this view, the Ingenuity Pathway analysis on the selected up- and downregulated genes (Figure S3B) indicates a modification of the lipid metabolism and a reduction of the oxidative phosphorylation activity in imosT1-Myc hearts. The top networks identified by this analysis for the upregulated, downregulated, and joint gene sets are again the networks activated in response to cardiac overload (Figures 3B and 3C). In agreement with these results, we found that the expression of the atrial natriuretic peptide was clearly activated in a patchy pattern in the ventricles of the imosT1-Myc mosaic hearts (Figure S3D).

Given the known functions of Myc in cardiomyocytes, the pathways detected likely result from cell-autonomous Myc functions and may relate to the ability of Myc-overexpressing cardiomyocytes to replace the WT cardiomyocyte population. In addition, the gene set enrichment study identified the activation of the apoptosis regulation and inflammation pathways in imosT1-Myc hearts, which could be related to the death and removal of WT cardiomyocytes. We therefore used the imosT1-Myc/T1p35 mosaics to undertake a functional study of the involvement of cell death. This analysis showed that p35 expression largely rescues the ECFP cell population (Figures 6C, 6G, and 6H). These results indicate that adult cardiomyocytes undergo Myc-induced cell competition, which progresses by elimination of WT cardiomyocytes and their replacement by cardiomyocytes with high Myc levels. We then analyzed whether increased proliferation of the Myc-overexpressing population is contributing to this phenomenon. We found that BrdU incorporation was 4-fold more frequent in the EYFP-Myc cardiomyocytes than in the WT cardiomyocytes of imosT1-Myc mosaic hearts (Figure 7B). This increase did not alter the proportion of mononucleated cardiomyocytes (Figure 7C), suggesting that the balance between mononucleated cardiomyocyte division and binucleation is preserved.

To directly assess the involvement of apoptosis in the cardiomyocyte population shift, we analyzed the TUNEL pattern in adult imosT1-Myc mosaics; however, we found no significant differences in TUNEL frequency between the EYFP-Myc and ECFP-WT cell populations. These results suggested that, unlike the situation during development, apoptosis might not be involved in the elimination of WT cardiomyocytes in adults, despite the activation of apoptotic pathways detected by RNA-seq. We then explored whether alternative cell-death pathways could be operating in postnatal cardiomyocytes. Given that p35, in addition to inhibiting apoptotic cell death, can also inhibit autophagic cell death (Martin and Baehrecke, 2004) and that many apoptosis regulators are also involved in autophagic cell death, we tested whether this pathway could be involved in postnatal cardiomyocyte cell competition. Analysis of the autophagic death-specific marker Beclin (Liang et al., 1999) showed rare positive cells in imosWT hearts (Figures 7D–7D’); however, the frequency of Beclin-positive cells increased by 5-fold in imosT1-Myc mosaic hearts (Figure 7E–7E’ and 7F). Moreover, the frequency of Beclin-positive cells within the imosT1-Myc mosaics was 9-fold higher in ECFP-WT cells than in EYFP-Myc cells (Figure 7G). These results indicate that autophagic cell death instead of apoptotic cell death is a major contributor to postnatal cardiomyocyte cell competition.

**DISCUSSION**

In this study, we demonstrate the ability of moderate Myc overexpression to induce cell competition in the developing and adult mouse heart. Previous studies showed that strong Myc...
overexpression during fetal life leads to cardiac hyperplasia due to cardiomyocyte hyperproliferation, while overexpression in adults leads to cardiac hypertrophy due to cardiomyocyte overgrowth (Jackson et al., 1990; Xiao et al., 2001). In contrast, we found that the Myc overexpression levels provided by the endogenous promoter of the Rosa26 locus do not lead to cardiac hypertrophy or hyperplasia. These results agree with previous evidence of ubiquitous MycERβ expression from the Rosa26 locus, which did not induce cardiac hypertrophy even when two alleles were present (Murphy et al., 2008). A molecular signature typical of the response to cardiac overload however was activated. The activated pathways (Nppa, HGF) are cardioprotective and stimulate benign adaptation to increased cardiac function demands (Kishimoto et al., 2001; Kuhn et al., 2002; Madonna et al., 2012). In particular, the HGF pathway is not only involved in the cardiac overload response but also stimulates cardiac regeneration (Madonna et al., 2012). The activation of these pathways in the absence of cardiac overload, or in the presence of increased cardiac demand due to intense exercise, did not result in functional impairment. In fact, the EGF pathway, involved in pathological cardiac hypertrophy (Lee et al., 2011), was found inhibited in the Myc mosaic hearts. The Myc levels used here therefore can be considered “homeostatic” in the heart, since hearts exposed to these levels stay within normal anatomical and functional parameters. Interestingly, these expression levels provided in a mosaic fashion are enough to trigger cell competition, thereby enabling Myc-high cardiomyocytes to eliminate neighboring WT cardiomyocytes and expand to replace them. These results identify a window in which Myc level fluctuations can affect cardiomyocyte behavior to promote homeostatic changes in myocardial cell composition without affecting organ development and function.

These observations highlight the remarkable ability of fetal cardiomyocyte populations to undergo changes in composition without disrupting cardiac function. Previous studies showed that in mosaic hearts composed of wild-type cardiomyocytes and others carrying a deleterious mutation, the wild-type cardiomyocytes overproliferate during development to compensate for the loss of mutant cardiomyocytes (Drenckhahn et al., 2008). These studies indicate that the fetal heart bears sensing mechanisms that detect the loss of functional cardiomyocytes and promote their replacement. Our present results show that this replacement ability can also be stimulated by cell competition, whereby even undamaged wild-type cardiomyocytes can be eliminated and replaced by more competitive cells, without compromising cardiac homeostasis. Interestingly, this ability is retained during adult life, albeit at a notably slower pace with respect to that observed during development. In Drosophila, damaged postmitotic cells in the ovary can be eliminated and compensated for by hypertrophy of the remaining healthy cells (Tamori and Deng, 2013), while in the eye, postmitotic cells become refractory to cell competition (Tyler et al., 2007). Here, we found that, despite the predominant postmitotic nature of adult cardiomyocytes, the loss of the outcompeted population is not compensated by hypertrophy of winner cells but through overproliferation.

The mechanisms by which neighboring cells compare their fitness during cell competition in the mammalian embryo remain unknown, but a common theme of cell competition in the epiblast and the developing heart is the elimination of loser cells by apoptosis. In fact, in the fetal heart, we did not observe overt differences in proliferation between the two mosaic populations. This result is in apparent conflict with the fact that overexpansion of Islet-Cre-recombined cardiomyocyte population requires overproliferation and with the fact that the relative reduction of the WT cardiomyocyte population in the Nkx2.5-Cre-recombined mosaics requires compensatory proliferation to preserve normal heart size. The 5.7x expansion of the IsletCre-recombined population, however, involves only 2.5 extra cell cycles per cell in the 11 days between the activation of the driver at E7.5 and birth. This yields a total of 0.22 extra divisions per cell and day. In the case of the studies with the Nkx2.5Cre driver, between E8.5 and E11.5, a 60% reduction in the original 25% WT cardiomyocyte population was observed, which represents a 15% of the total cardiomyocyte population. To replace the 15% missing cardiomyocytes, only 0.15 extra cell divisions/cardiomyocyte would be required during the 3-day observation period. The degree of overproliferation required to explain the changes observed is therefore small and might not be experimentally detectable, especially since PHH3 and BrdU alone might not be enough for a full characterization of the cell proliferation rate cell proliferation.

In adult cardiomyocytes, however, we found a clear increase in the proliferative ability of winner cardiomyocytes, which likely contributes to the replacement of the loser population. While this increased proliferation capacity might be essential for the competitive ability, it is clearly not sufficient, and elimination of the loser population is still a requirement for cell competition in the adult heart. In fact, this overproliferation is most likely only compensatory for the loss of WT cardiomyocytes, since the homogeneous overexpression of two ROSA26-MycER copies does not lead to overproliferation in the adult heart (Murphy et al., 2008). The compensatory nature of this overproliferation would also explain the absence of cardiac overgrowth upon Myc mosaic overexpression.

These results suggest that fitness comparison between neighbors and death of the less-fit cells is a common theme in cell competition in very different scenarios. The fact that autophagic instead of apoptotic cell death is observed in adult cardiomyocytes could be more related to the specific features of adult cardiomyocytes than to the cell-competition phenomenon. Dying cells are normally eliminated by macrophages, but the size of an adult cardiomyocyte is about 100 times that of a macrophage, so a phase of self-destructive autophagy might be necessary before they can be eliminated by macrophages in a controlled manner. In fact, the typical example of autophagic death in Drosophila involves as well the elimination of giant cells of the salivary gland (Martin and Baehrecke, 2004). These considerations are in agreement with the predominance of TUNEL-negative autophagic cardiomyocyte death reported in heart failure patients (Knaapen et al., 2001).

The fact that cardiomyocytes undergo Myc-induced cell competition suggests that cell competition operates during normal heart development for the elimination of impaired cardiomyocytes unable to meet the anabolic rates demanded in the myocardium. Anabolism-induced cell competition thus appears
as a widespread phenomenon in mammalian tissues and not restricted to stem cell pools like the epiblast. There is an important difference, however, between endogenous cell competition in the epiblast and how it might operate during cardiogenesis: whereas epiblast development is characterized by a strong pattern of cell competition-associated apoptosis, during cardiogenesis, cardiomyocyte death is very infrequent (Poelmann et al., 2000). This suggests that while cell competition would work as a cell quality-control mechanism in both scenarios, in the epiblast it functions as a constitutive program, whereas during cardiogenesis it is used contingently, only if impaired cardiomyocytes appear. Since cardiomyocyte competition ability extends into adult life, it will be very interesting in the future to study whether cell competition is involved in maintaining tissue fitness during aging and whether it can contribute to natural or induced repair of cardiac insults in which cardiomyocytes are lost or impaired.

EXPERIMENTAL PROCEDURES

Mouse Strains
The iMOS(St), iMOS(St)-Myc, and iMOS(St)-Myc(T2-p36) mouse lines have been described (Clavería et al., 2013). Here, they were used in combination with different Cre-expressing lines to induce genetic mosaics in the developing and adult mouse heart. Experimental embryos or born mice were generated from crosses of homozygous iMOS females with males carrying the different Cre drivers: Nkx2.5Cre (Stanley et al., 2002), Islet1Cre (Yang et al., 2006), and aMHCreMer (Sohal et al., 2001). Mice were genotyped by PCR (Clavería et al., 2013). To induce recombination in iMOS:zMHCreMer mice, they were fed for 1 month with pellets containing tamoxifen at 40 g/kg (Teklad ref. TD.07262).

Confocal Microscopy
Whole embryonic hearts or histological sections were imaged with a Nikon A1R confocal microscope using 405, 458, 488, 568, and 633 nm wavelengths and 20×/0.75 dry and 40×/1.30 oil objectives. Areas occupied by EYFP and ECFP cells were quantified using the threshold detection and particle analysis tools in ImageJ (NIH; http://rsb.info.nih.gov/ij/). To calculate the relative frequency of ECFP cells, the percentage of ECFP area observed was divided by the average percentage in iMOS(St) mosaics. All percentages were normalized to a 100% value in the WT mosaic. ECFP was scored either by direct identification of native ECFP fluorescence or by subtracting the area of native EYFP fluorescence reported in this paper is GSE58858.

ACCESSION NUMBERS
The NCBI Gene Expression Omnibus database accession number for the RNA-seq data reported in this paper is GSE58858.

SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures, three figures, and one movie and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2014.08.005.

ACKNOWLEDGMENTS
We thank J.L. de la Pompa for comments on the manuscript, V. Garcia for mouse work, E. Arza and A.M. Santos for help with microscopy and 3D reconstruction, J. García-Prieto for help with cardiomyocyte isolation, A.V. Alonso for the echocardiography assays, F. Sánchez-Cabo for statistics, and S. Bartlett for text editing. The CNIC Genomics unit performed the RNA sequencing procedures. This work was supported by grants BFU2012-31086 and RD12/0109/0005 (ISCIII) from the Spanish Ministry of Economy and Competitiveness (MINECO) and grant P2010/BMD-2315 from the Madrid Regional Government. C.V. is supported by a FPI grant from the MINECO. The CNIC is supported by the MINECO and the Pro-CNIC Foundation.

Received: February 5, 2014
Revised: April 21, 2014
Accepted: August 1, 2014
Published: September 4, 2014

REFERENCES


Wu wei